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ABSTRACT
The School of Graduate Studies
The University of Alabama in Huntsville
Degree Doctor of Philosophy

Program _Biotechnology Science and Engineering_

Name of Candidate __Brittany N. Lasseigne__
Title _Analysis of DNA Methylation and Copy Number Variation in Renal Cell
Carcinoma_

Renal cell carcinoma (RCC) is the 10th most commonly diagnosed cancer in the
United States and its incidence is increasing. It is difficult to detect early and is relatively
non-responsive to traditional radiation and chemotherapies. Previous work demonstrates
the value of measuring copy number variation (CNV) and DNA methylation changes in
RCC, but diagnostic biomarkers and additional treatment options in the clinic are still
needed.
This study examined genome-wide DNA methylation and CNV in RCC tumor
and benign adjacent kidney tissues from 101 clinically-annotated patients. Analyses
revealed widespread DNA methylation and copy number differences between tumor and
benign tissues, particularly in immune, G-protein coupled receptor, and metabolismrelated genes. Also reported is a panel of DNA methylation biomarkers that successfully
distinguish tumor from benign tissue and validation of these markers in The Cancer
Genome Atlas RCC datasets. Additionally, variable DNA methylation and copy number
profiles effectively classified the patients into distinct risk of recurrence groups for
potential assessment of alternative treatment therapies. Overall, increased global DNA
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CHAPTER 1

INTRODUCTION

1.1 Renal Cell Carcinoma Incidence, Diagnosis, and Treatment
Renal cell carcinoma (RCC) is the 10th most commonly diagnosed cancer in the
United States with nearly 60,000 new cases, 13,000 deaths (Ferlay et al., 2010), and an
economic burden in the billions of dollars, annually (Shih et al., 2011). World-wide,
there are approximately 271,000 new cases and 116,000 deaths from RCC each year
(Howlader et al., 2009). RCC incidence has risen by a rate of 2-3% per year since the
1970s.

Comparison to diagnosis of other cancers, like renal pelvis carcinoma,

demonstrates this rising incidence is not solely because of improved imaging
technologies, such as CT scans (Chow et al., 1999). The escalation of RCC could be due
to increased obesity or exposure to chemicals, but sufficient studies have not explored
these variables.
RCC is typically diagnosed via imaging and currently there are no biomarker
panels clinically available for early detection or prognosis. Standard of care is resection
and if the disease is caught at an early stage and found confined to the kidney (60% of
patients), 5-year survival rates are 91%. However, once the cancer has spread to nearby
1

organs and lymph nodes (20% of patients), 5-year survival rates drop to 62%. With
distant metastasis (20% of patients), 5-year survival rates plummet to 12%. Because
symptoms associated with low stage cancer are rare and later symptoms are non-specific
(side pain, weight loss, fever, fatigue, blood in urine), diagnosis is challenging. Patients
only achieve durable complete response (survival greater than 10 years) when the cancer
is caught early and completely removed by surgery or in metastatic cases, in a limited
number of patients treated with interleukin-2 immunotherapy. However, interleukin-2
therapy is associated with toxicity and it is unclear why some patients are responsive and
others are not (Jonasch et al., 2012).
Renal cell carcinoma is often described as non-responsive to traditional radiation
and chemotherapies (Chow et al., 2009; Howlader et al., 2009) because of disappointing
phase II drug trials (Buti et al., 2013). Drugs that block vascular endothelial growth
factor (VEGF) like sorafenib tosylate and sunitinib malate, or inhibit the mechanistic
target of rapamycin (mTOR) pathway like temsirolimus and everolimus, have been
approved for use in metastatic RCC in recent years, but these drugs have harsh sideeffects and only increase disease-free progression time by weeks to months (Jonasch et
al., 2012). There is evidence that combination chemotherapy in advanced disease, or in
tumors with sarcomatoid features, may have anti-tumor activities, but additional studies
of available drugs and new drug targets are needed (Buti et al., 2013).

1.2 Renal Cell Carcinoma Subtypes
RCC develops from specialized cells in the nephron and is comprised of several
histological subtypes associated with varying survival statistics and recurrence rates. The
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World Health Organization (WHO) currently recognizes almost 50 distinct renal
neoplasms and there is an on-going effort to characterize both the clinical and genetic
features of these emerging subtypes. In addition to pathological analyses, WHO now
includes genetic alterations as distinguishing factors for some of these subtypes(LopezBeltran et al., 2009, 2013).
The most common, comprising approximately 75% of RCC cases, is clear cell
renal cell carcinoma (ccRCC) which arises from the proximal convoluted tubule (where
the majority of filtrate reabsorption occurs).

ccRCC is characterized by a loss of

chromosome 3p and inactivation of von-Hippel Lindau (VHL), a tumor suppressor
involved in the regulation of gene expression by oxygen. It has a worse prognosis than
papillary RCC (pRCC) or chromophobe RCC (ChRCC) and may progress into a
sarcomatoid carcinoma.

Sarcomatoid carcinomas are characterized by a higher

proliferation rate, increased dedifferentiation, increased local tissue invasion, and
increased metastasis. All of the most common RCC subtypes are known to present
sarcomatoid features and there is speculation that sarcomatoids are actually
dedifferentiated RCC tumors and not an independent subtype (Cheville et al., 2004; de
Peralta-Venturina et al., 2001; Lopez-Beltran et al., 2009).
Papillary RCC (pRCC) also arises from the proximal convoluted tubule, but is
less aggressive than ccRCC and is characterized by amplification of chromosomes 7 and
17. pRCC accounts for approximately 10% of RCC cases. The other common RCC
subtype (approximately 5% of RCC cases), chromophobe RCC (ChRCC), is
characterized by large pale cells and arises from the collecting duct.

ChRCC and

oncocytomas, a benign tumor, often present with many of the same features. Both are
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thought to be derived from the same cell type and have mitochondrial rearrangements.
While ChRCC is less aggressive than ccRCC or pRCC, oncocytomas may actually be the
benign form of ChRCC. The most prominent genetic feature of ChRCCs is many
chromosomal monosomies, while oncocytomas are largely diploid. There are many other
rare subtypes and unclassified cases of RCC (Hagenkord, Gatalica, Jonasch, & Monzon,
2011; Lopez-Beltran et al., 2009; Srigley & Delahunt, 2009).

1.3 Renal Cell Carcinoma Etiology and the Role of VHL
Known environmental risk factors for RCC include obesity, hypertension, and
cigarette smoking, but all have weak association (Dhôte, Pellicer-Coeuret, Thiounn,
Debré, & Vidal-Trecan, 2000). Less than 4% of cases are hereditary, and the etiology of
the disease remains largely uncharacterized (Lopez-Beltran et al., 2009, 2013).
Hereditary ccRCC cases are associated with defective VHL and 50% of sporadic ccRCC
do not produce wild-type VHL (Kim & Kaelin, 2004). VHL is a protein that functions as
a tumor suppressor through regulation of hypoxia-inducible factor (HIF), a transcription
factor comprised of an α and β subunit, which regulates targets based on the presence or
absence of oxygen. When a cell is hypoxic (or does not express VHL), HIF activates a
cassette of 100 to 200 genes, in turn adapting the cell to hypoxic conditions via
erythropoietin (EPO), VEGF, and other mTOR pathway members (Li & Kaelin, 2011).
Despite the prevalence and importance of VHL inactivation in ccRCC, it is clear
VHL is not the cause of renal cancer. Not only is VHL mutation in mice kidneys not
sufficient to cause cancer, but patients with hereditary VHL disease often have hundreds
of preneoplastic lesions, while only 40% develop kidney cancer (Ong et al., 2007;
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Rankin, Tomaszewski, & Haase, 2006). Recent studies have shown the potential for
malignant ccRCC transformation is correlated with VHL disruption coupled with
excessive HIF2α activity (Mandriota et al., 2002; Purdue et al., 2011). Genome-wide
association studies of RCC have indeed pointed to HIF2α, as well as scavenger receptor
class B, member 1 (SCARB1), a cell surface receptor for high-density lipoprotein (both
below genome-wide significance), and inositol 1,4,5-trisphosphate receptor, type 2
(ITPR2), a calcium channel and inositol triphosphate receptor, through a meta-analysis
(Guo et al., 2012; Purdue et al., 2011). Neither SCARB1 nor ITPR2's role in RCC is
known.

1.4 Genomic Studies in Renal Cell Carcinoma
Integrated genomics studies in RCC have demonstrated the importance of
chromatin remodeling, epigenetic reprogramming via histone modifications, and the
remodeling of cellular metabolism as RCC features (Creighton et al., 2013; Dalgliesh et
al., 2010; Guo et al., 2012; Varela et al., 2011). These sequencing and genomic data
integration studies underscore the profuse genetic heterogeneity existing between
patients, suggesting further integration of genomic data sets and additional analysis
approaches are necessary (Creighton et al., 2013; Dalgliesh et al., 2010; Gerlinger et al.,
2012; Varela et al., 2011). In particular, RCC etiology and disease progression is still
largely uncharacterized, and the need for diagnostic biomarkers, prognostic biomarkers,
and novel therapeutic targets remains unmet. Both chromosomal aberrations and DNA
methylation alterations have been identified as early and important events in RCC (Arai
& Kanai, 2011).
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5-methylcytosine occurs with the covalent addition of a methyl group to a
cytosine base, and is often referred to as the "fifth base" because of its role in the
differential expression of nearby genes, including dysregulation in cancer (Laird &
Jaenisch, 1994; Montero et al., 1992; Sharma, Kelly, & Jones, 2010; Tsai & Baylin,
2011; Ushijima, 2005) (Figure 1.1). Typically, 5-methylcytosine in a gene promoter
causes transcriptional silencing and this process is essential for proper development, Xchromosome

inactivation,

maintaining

chromosome

architecture,

and

genomic

imprinting. CpGs are not distributed evenly in the genome, but are clustered near genes
in dense, CpG-rich regions known as CpG islands. The majority of CpGs in the human
genome are methylated, but most CpG islands remain unmethylated during normal
development and in differentiated tissues. Conversely, repetitive regions of the genome
are heavily methylated to silence transposable elements and non-coding DNA, as well as
maintain chromosomal stability. DNA methylation is often altered in tumor cells with
CpG islands exhibiting increased DNA methylation and long sequence repeat regions
exhibiting decreased DNA methylation in tumor compared to normal tissue (Sharma et
al., 2010).
Previous genome-wide studies of DNA methylation in RCC (Arai & Kanai, 2011;
McRonald et al., 2009; Morris et al., 2011) have identified regions of differential
methylation between benign kidney tissue and tumor kidney tissue. They have suggested
increased DNA methylation is associated with higher cancer grade (Creighton et al.,
2013), or more aggressive cancer (Arai et al., 2012; Arai, Ushijima, & Tsuda, 2008).
DNA methylation is a promising source of early diagnostic biomarkers because these
changes are often early events in carcinogenesis (Kanai, 2010), including in precancerous
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RCC lesions (Arai & Kanai, 2011), and DNA methylation changes are a stable DNA
mark that can be quantitatively measured (Mikeska, Bock, Do, & Dobrovic, 2012).
Candidate gene studies of gene promoter methylation in RCC have revealed the potential
for identification of DNA methylation diagnostic biomarkers (Battagli et al., 2003;
Hoque et al., 2004), but previous genome-wide studies have not identified biomarkers for
clinical use. Additionally, DNA methylation levels in the genome have been linked to
different patient response to chemotherapeutics as in other cancers.
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Figure 1.1 Role of DNA methylation in promoter regions of genes.
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Proper chromosomal segregation is required with every cell division to maintain a
diploid genome. Copy number variation (CNV) is a genomic alteration of this diploid
karyotype, where sections of DNA are deleted or amplified. Many mechanisms related to
homologous and non-homologous recombination have been implicated in CNV
generation (Gordon, Resio, & Pellman, 2012), and these variations can affect regulatory
regions or coding regions, resulting in protein expression changes (Figure 1.2). CNVs
occur at a high frequency in cancer, with reports suggesting 25% of a typical cancer cell
genome has whole-arm or whole chromosome structural variants and 10% of a typical
cancer cell genome has focal structural variants (Beroukhim, Mermel, et al., 2010).

In

cancer this has profound effects. Oncogenes can be amplified and activated by over
expression, while tumor suppressor genes can be deleted and inactivated by decreased
expression (Michels, De Preter, Van Roy, & Speleman, 2007).
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Figure 1.2 Potential for dose-dependent gene expression with copy number variation.
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Current WHO guidelines for identification of some RCC subtypes includes the
use of chromosomal variation (for example, chromosome 3p loss in ccRCC and
chromosomes 7 and 17 amplification in pRCC), but previous studies investigating
genome-wide CNV in RCC used lower resolution technologies, small sample numbers,
or both (Beroukhim, et al., 2010; Cifola et al., 2008; Dondeti et al., 2012; Klatte et al.,
2009; Monzon et al., 2008; Toma et al., 2008; Yoshimoto et al., 2007).

Gross

chromosomal instability in other cancers has been linked to taxane resistance and varying
response to chemotherapeutics (McClelland, Burrell, & Swanton, 2009), but this
phenomenon has not been explored in RCC and genes affected by CNV in a subtype
specific manner has largely gone uninvestigated.

1.5 Project Objectives
Despite VHL pathway involvement in most RCC patients, the cancer's etiology
and progression is not well characterized, diagnostic and prognostic biomarkers are
needed in the clinic, and additional drug targets for advanced disease are required.
Examining gene expression, DNA methylation, copy number variation, DNA sequencing,
and GWAS alone have not fulfilled these needs. Recent genomics integration studies
(Creighton et al., 2013; Sato et al., 2013) failed to examine the relationship between
global CNV, DNA methylation, and patient survival in RCC as seen in other cancers
(Birkbak et al., 2011), or establish biomarkers that could be translated to the clinic.
Additionally, RCC sequencing projects have underscored the profuse genetic
heterogeneity existing between cases, suggesting integrated data set approaches are
necessary (Varela et al., 2011).
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Systems biology approaches with multiple data types in clinically-annotated
tumor sets have yielded invaluable information towards building a comprehensive picture
of the processes leading to oncogenesis, as well as characterization of tumor subtypes,
candidate biomarkers, and potential therapeutic targets. For example, in glioblastoma,
somatic mutations and DNA copy number data together establish patterns identifying
different subtypes that relate to both the cancer's neural lineage and response to
aggressive therapy, that cannot be identified by one of these data types alone (Verhaak et
al., 2010). Similarly, integration of multiple genomic data types in ovarian cancer has
pointed to 68 therapeutic targets and associated global patterns affecting disease survival
and progression (Cancer Genome Atlas Research Network, 2011).
An integrated genomics approach leveraging both copy number variation and
DNA methylation will yield valuable information on genes, pathways, and global
signatures involved in renal cell carcinoma etiology, progression, and recurrence not
possible with a single data type. Examining copy number events and DNA methylation
alterations in the same patient set not only allows for exploration of global patterns, but
also if the same genes are affected by different mechanisms in different patients. There is
already precedent for this in kidney cancer--it is well documented using targeted
approaches that in most cases, one VHL allele is inactivated through a chromosome 3p
deletion event and the other allele has an intragenic mutation, or both alleles are silenced
by increased DNA promoter methylation in ccRCC (Beroukhim, Brunet, et al., 2010).
Also, discovery and validation of biomarkers to aid in early detection of kidney cancer
would improve the overall survival rate of patients by allowing the cancer to be treated
by resection before metastasis and both CNV and DNA methylation alterations have been
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demonstrated as early events in RCC. Additional drug targets and an understanding of
why some patients respond to immunotherapies would also improve treatment options
and patient quality of life.
To identify genomic variation in RCC and address these needs, I profiled 101
kidney tumor and benign adjacent kidney tissues in clinically-annotated patients. Using a
variety of analysis tools including linear regression modeling, hierarchical and consensus
clustering, limited peel-off CNV algorithms, and shrunken centroids classifiers, I
investigated genetic alterations between tumor and normal tissues, recurrent and nonrecurrent tissues, as well as subtype-specific variation. I also examined the prevalence of
microsatellite instability (MSI) in the context of DNA methylation and copy number
alterations of mismatch repair genes in RCC tumors. This study reports the first validated
diagnostic biomarker panel for the detection of general RCC, as well as ccRCC, and
offers valuable insights into RCC etiology, progression, and potential drug targets.
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CHAPTER 2

DNA METHYLATION AND COPY NUMBER VARIATION PROFILING REVEALS
NOVEL BIOMARKERS AND RECURRENCE RISK GROUPS IN RENAL CELL
CARCINOMA

2.1 Introduction
Renal cell carcinoma (RCC), the 10th most commonly diagnosed cancer in the
United States, accounts for 4% of all cancer, and incidence is rising by 2-3% annually
(Chow et al., 1999; Ferlay et al., 2010; Howlader et al., 2009).

RCC is typically

diagnosed via imaging and currently there are no biomarker panels clinically available.
Standard of care is resection, and early detection with tumor confined to the kidney (60%
of patients) is associated with high 5-year survival rates. However, early symptoms are
rare and later symptoms are non-specific, making diagnosis a challenge. With metastasis
beyond the kidney (40% of patients), the 5-year survival rate decreases dramatically,
because RCC is typically non-responsive to traditional radiation and chemotherapies
(Chow et al., 2009; Howlader et al., 2009). Drugs blocking vascular endothelial growth
factor (VEGF) like sorafenib tosylate and sunitinib malate, and inhibitors of the
mechanistic target of rapamycin (mTOR) pathway, such as temsirolimus and everolimus,
14

have been approved for use in metastatic RCC recently, but have severe side-effects with
limited efficacy and only moderate increases in disease-free progression from weeks to
months (Jonasch et al., 2012). Some metastatic RCC patients receiving interleukin-2
immunotherapy achieve durable complete response (survival greater than 10 years) after
therapy, but interleukin-2 therapy is also associated with toxicity and it is unclear why
some patients are responsive and others are not (Jonasch et al., 2012). Discovery of
biomarkers to aid in early detection of kidney cancer would improve the overall survival
rate of these patients by allowing the cancer to be treated by resection before metastasis.
Additional drug targets and an understanding of why some patients respond to
immunotherapies would also improve treatment options and patient quality of life.
RCC is classified based on histological markers and the part of the nephron the
cancer originated from (Rini, Campbell, & Escudier, 2009). The most common subtype,
comprising 75% of cases, is clear cell renal cell carcinoma (ccRCC) and arises from the
proximal convoluted tubule. This predominant subtype is characterized by inactivation
of the von Hippel-Lindau (VHL) tumor suppressor, which interacts with hypoxia
inducible factors and alters cellular oxygen sensing in tumors (Kim & Kaelin, 2004).
Less common subtypes include papillary RCC (10% of cases), which also derives from
the proximal convoluted tubule, but is less aggressive than ccRCC, and chromophobes
(5% of cases) that arise from the collecting duct and are associated with a very high
survival rate. Additional atypical subtypes arise from other parts of the nephron (LopezBeltran et al., 2009).
Genomics-based studies demonstrated the importance of chromatin remodeling,
epigenetic reprogramming via histone modifications, and remodeling of cellular
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metabolism as features of RCC (Creighton et al., 2013; Dalgliesh et al., 2010; Guo et al.,
2012; Varela et al., 2011). Sequencing and genomic data integration studies in RCC have
demonstrated a profuse genetic heterogeneity between patients, and underscores the need
for additional integrated analysis approaches (Creighton et al., 2013; Dalgliesh et al.,
2010; Gerlinger et al., 2012; Varela et al., 2011).
Candidate gene studies of gene promoter methylation in RCC have revealed the
potential for identification of DNA methylation diagnostic biomarkers (Battagli et al.,
2003; Hoque et al., 2004). Previous genome-wide studies of DNA methylation in RCC
either lacked comparison of tumor methylation profiles to benign tissue, or did not
address the identification of diagnostic biomarkers for future clinical application. Copy
number variations (CNVs) have also been established as playing an important role in
RCC (Arai & Kanai, 2011), but while past studies identified CNV changes in RCC,
including the well-characterized loss of the 3p arm in ccRCC, the relationship between
global CNV, DNA methylation, and patient survival seen in other cancers has not been
analyzed in RCC (Birkbak et al., 2011).
In this study, I profiled DNA methylation and CNVs in parallel across 101 RCC
patients with Illumina HumanMethylation27 andHuman1M-Duo microarrays. This novel
integrated analysis of resected kidney tumor and benign adjacent kidney tissue with
clinical information identified molecular changes and pathways associated with RCC
etiology. These data led to a biomarker panel capable of differentiating kidney tumor
from benign adjacent kidney tissue and subgroup classification by distinct incidences of
recurrence. This study provides insight into the etiology and recurrence of RCC and
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provides a framework for molecular diagnostics to shape clinical detection of RCC in
patients.

2.2 Methods
Rick Myers, Devin Absher, and Jim Brooks assisted with planning experiments
and analyzing data. I worked with Devin Absher and his lab to perform the DNA
methylation and copy number variation assays.

Preti Jain performed ComBat

normalization of the DNA methylation data. Todd Burwell contributed to the statistical
analysis.

2.2.1 Tissue Collection and Preparation
Kidney tissues used in this study were collected at Stanford University with
patient's informed consent under IRB-approved protocols. Sections were examined by a
pathologist and clinical information associated with each patient is summarized in
Appendix A. DNA was isolated from tissues using the QIAGEN AllPrep DNA kit
(QIAGEN) following the manufacturer's protocol.

2.2.2

Sodium Bisulfite Conversion and Illumina Infinium HumanMethylation27
Assay
Sodium bisulfite conversion of gDNA was performed using the EZ-96 DNA

Methylation Kit (Deep-well format, ZymoResearch) with the alternative incubation
protocol for the Illumina Infinium Methylation Assay, as described by the manufacturer.
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Five hundred nanograms of sodium bisulfite-converted gDNA from patient tissues was
assayed by Infinium HumanMethylation27 RevB Beadchip Kits (Illumina) per the
manufacturer's protocol.

2.2.3 Beta Score Calculations, Filtering, and Batch Normalization of DNA
Methylation Data
HumanMethylation27 array results were analyzed using Illumina BeadStudio
software with the Methylation Module v3.2. All negative beta scores were converted to
zero and beta scores with an associated detection p-value>0.01 were converted to "NA"
and filtered from analysis. To correct any array-by-array variation, all missing values
were imputed with KNN Impute, followed by array batch normalization using the
ComBat R-package (Johnson, Li, & Rabinovic, 2007). Previously imputed values were
converted back to "NA" for all further analyses. CpGs with "NA" in greater than 10% of
tissues were removed from the data set. As previously reported, I removed CpGs with
questionable mapping or CpGs that included a SNP of >3% minor allele frequency within
15 bp of the assayed CpG to avoid potential variation in probe hybridization (Kobayashi
et al., 2011).

After quality control and filtering, I had 96 patients with 26,148 CpGs

assayed in both kidney tumor and benign adjacent tissues.

2.2.4 Linear Mixed, Linear, and Logistic Regression Analysis
For the regression analysis I used RStudio (version 0.97.551) in R (version 3.0.0).
For the linear mixed model analysis of the DNA methylation data I used the lme
command--treating patient as a random effect and age and gender as fixed effects. I used
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the glm command with family set to binomial for the logistic regression of the diagnostic
biomarkers. I selected the best model based on a maximum ROC (receiver operating
characteristic) curve area and a minimum AIC (Akaike's information criterion) value.
The lm command was used for the linear regression of the methylation changes between
consensus class with patient gender and grade as covariates. All regression models have
p-values adjusted for multiple hypothesis testing utilizing the Benjamini and Hochberg
(BH) algorithm and significant CpGs have an adjusted p-value<0.05 (Foulkes, 2010).

2.2.5 Hierarchical Clustering and Consensus Clustering
Prior to hierarchical clustering, beta scores were mean-centered. Hierarchical
clustering of the DNA methylation data by both gene and array was done using Cluster
3.0 with average linkage (Eisen, Spellman, Brown, & Botstein, 1998).

Consensus

clustering was performed on all filtered CpGs using the ConsensusCluster Plus package
in R with k-means clustering from k=2 to k=10 and Euclidean distance for 1000
repetitions (Wilkerson & Hayes, 2010). Kaplan-Meier curves were produced for the
clusters at each k and compared with a Bonferroni-corrected log-rank test.

2.2.6 Prediction Analysis of Microarrays
PamR (version 1.54) analysis was performed on all filtered CpGs as described in
the PamR manual with RStudio (version 0.97.551) in R (version 3.0.0) (Tibshirani,
Hastie, Narasimhan, & Chu, 2002). Based on visual examination of the training errors
and cross-validation results, I minimized the miss-rate and set the shrinkage threshold to
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10.74 for all tumor and benign adjacent normal classification, and 14.8 for clear cell
tumor and benign adjacent normal classification.

2.2.7 Illumina Human 1M-Duo Assay and JISTIC Analysis
Two hundred and fifty nanograms of gDNA from patient tissues were assayed by
Infinium Human1M-Duo Beadchip Kits (Illumina). The assay was performed using the
protocol as described by the manufacturer. After quality control, I had 100 patients with
both kidney tumor and benign adjacent normal data. Log R ratios were obtained from
BeadStudio. Copy number variation analysis was performed between the kidney tumor
data and the paired benign adjacent normal data utilizing the focal (limited peel-off)
algorithm in the Java implementation of JISTIC per the manual's instructions (SanchezGarcia, Akavia, Mozes, & Pe’er, 2010).

2.2.8 GO-term and GSEA Analysis
CpGs and regions identified as significant were associated with the closest gene
and then those genes were analyzed for common pathways and functions.

Terms

reported have an adjusted p-value<0.05. GO-term analysis was performed using the web
version of GOrilla (Eden et al., 2009) and GSEA was performed using the web version of
GSEA (Mootha et al., 2003; Subramanian et al., 2005) with KEGG, BIOCARTA, and
REACTOME gene sets selected.
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2.2.9 TheCancer Genome Atlas Data
The

Cancer

Genome

Atlas

(TCGA)

Illumina

HumanMethylation27and

HumanMethylation450 Level 3 array results were downloaded for all kidney cancer
patients available at the time of manuscript preparation. Diagnostic biomarker validation
for ccRCC patients utilized HumanMethylation27 tumor and matched benign adjacent
normal ccRCC TCGA data.

Diagnostic biomarker validation for the general RCC

patients utilized both HumanMethylation27 and HumanMethylation450 tumor and
matched benign adjacent normal ccRCC, pRCC, and ChRCC TCGA data.

RNA

expression data was downloaded for ccRCC patients utilizing the RNA-seq Level 3 data
available at the time of manuscript preparation.

2. 3 Results

2.3.1Identification of Differential Methylation Between Kidney Tumor Tissue
and Benign Adjacent Kidney Tissue
Clinical data was collected for all patients, including follow-up and recurrence
data on 80 of these patients (see Appendix A). Patient grade, stage, and age were
compatible

with

risk

of

recurrence

(Howlader

et

al.,

2009).

Illumina

HumanMethylation27 microarrays interrogate 27,578 CpGs primarily in the promoter
regions of genes in the human genome. After quality control and filtering, I performed
the following DNA methylation analysis with 96 patients and 26,148 CpGs. To identify
CpGs carrying tumor-specific aberrant methylation, I performed linear mixed effects
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models with paired tumor/normal data at each CpG. These models treated patient ID as a
random effect and included gender and age as fixed effects. When I analyzed all CpGs
and patients with these models, 9,800 CpGs were significantly different between kidney
tumor and benign adjacent kidney tissue (FDR<0.05).

Of these, 5,155 CpGs had

increased DNA methylation in tumors and 4,645 CpGs had decreased DNA methylation
in tumors, compared to benign adjacent tissue.
Using the most significant CpGs from the linear mixed effects model (1,172
CpGs, FDR<1 X 10-10), I performed hierarchical clustering by tissue and CpG (Figure
2.1). I observed one cluster with shorter branch lengths that contained all but three of the
normal tissues (right, Figure 2.1). Most of the tumors were in the surrounding clusters
and off-shoots with longer branch lengths, indicating greater heterogeneity in the tumor
methylation profiles (Gerlinger et al., 2012).
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Figure 2.1 Hierarchical clustering of kidney tumor and kidney benign adjacent tissues
with most significant DNA methylation changes. Hierarchical clustering by both tissue
(columns) and CpG (rows) of 192 kidney tumor and kidney benign adjacent tissues with
linear mixed model significant CpGs (FDR<1 X 10-10;1,172 CpGs).
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To examine potential functional similarities among these DNA methylation
events, I performed a gene set enrichment analysis (GSEA) of the GO-terms and
pathways associated with genes nearest CpGs exhibiting increased and decreased
methylation in tumors compared to benign adjacent normals (Eden et al., 2009; Mootha
et al., 2003; Subramanian et al., 2005). I found that the majority of significant process
GO-terms associated with reduced methylation in tumors were immune-related.
Examples include defense response, immune response, inflammatory response, regulation
of leukocyte activation, regulation of T cell activation, and regulation of lymphocyte
activation. Wozniak, et al. recently reported increased gene expression of immunerelated genes in ccRCC patients and showed some of those genes were linked with
decreased methylation of proximal CpGs in The Cancer Genome Atlas (TCGA)
data(Wozniak et al., 2013). GSEA analysis of genes associated with decreased CpG
methylation in tumors revealed similar significant immune pathways and sets including T
cell receptor signaling, IL-12 mediated signaling, and leukocyte transendothelial
migration. GSEA also indicated decreased methylation in the promoter regions of genes
involved in G-protein coupled receptor (GPCR) signaling.
GO-terms associated with genes near CpGs with increased tumor DNA
methylation included cell-cell signaling and gated channel activity. Interestingly, GSEA
identified genes associated again with GPCR signaling, indicating differential DNA
methylation of these genes within subsets of the tumors.

I also found pathways

associated with integration of energy metabolism, extracellular matrix organization, and
WNT signaling. To my knowledge, this is the first report of widespread differential
methylation in genes related to GPCR signaling in RCC.
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I repeated the same regression analysis including only the 63 ccRCC patients and
found ~85% of the ccRCC significant CpGs (FDR<0.05) were shared with the significant
CpGs for all patients. I found significant DNA methylation changes for VHL, SETD2,
BAP1, and UQCRH, all genes previously shown to be mutated in RCC patients
(Dalgliesh et al., 2010; Varela et al., 2011). However, I did not see significant DNA
methylation changes for PBRM1, a gene previously shown to have truncating mutations
in RCC at a level only superseded by VHL(Varela et al., 2011), indicating transcriptional
silencing by DNA methylation is unlikely. Likewise, a gene set enrichment and GO-term
analysis of the significantly altered CpGs in the ccRCC patients revealed functions and
pathways very similar to the results for all of the patients.

2.3.2 Diagnostic DNA Methylation Biomarkers
To identify CpGs that may serve as diagnostic biomarkers, I used a classification
tool called Prediction Analysis of Microarrays (PAM) (Kobayashi et al., 2011; Tibshirani
et al., 2002). PAM utilizes a shrunken centroid classification algorithm to identify
significant CpGs whose DNA methylation characterizes tumor tissue from benign
adjacent tissue. When all 192 benign adjacent and tumor tissues were included in the
analysis, I identified 20 CpGs that discriminated between benign adjacent tissue and
tumor tissue. Using this list of 20 CpGs, I performed hierarchical clustering on both the
tissues and CpGs (Figure 2.2, panel A) and visual inspection shows 91 of 96 tumors
clustered together and 93 of 96 benign adjacent normals clustered together. Nineteen of
these 20 CpGs were significant in the linear mixed model analysis of differently
methylated CpGs between tumor and benign adjacent kidney tissue (FDR<0.05).
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Figure 2.2 Hierarchical clustering of kidney tumor and kidney benign adjacent tissues
with PAM classifier panel CpGs. (A) Hierarchical clustering by both tissue (columns)
and CpG (rows) of all 192 kidney tumor and kidney benign adjacent tissues with PAM
classifier panel CpGs(20 CpGs). (B) Hierarchical clustering by both tissue (columns)
and CpG (rows) of 126 clear cell kidney tumor and kidney benign adjacent tissues with
PAM classifier panel CpGs (11 CpGs).
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When I repeated this analysis with only the 63 clear cell patients, PAM identified
11 CpGs that discriminated between benign adjacent and tumor tissues. Hierarchical
clustering on both the tissues and the CpGs (Figure 2.2, panel B) shows an almost perfect
division with only one tumor clustering with the benign adjacent normals. These 11
CpGs were all significant in the previously described linear mixed model analysis of the
clear cell tumor data and the benign adjacent normal data (FDR<0.05).

Better

classification with the ccRCCs over all of the subtypes was most likely because of
increased heterogeneity in the DNA methylation data when including multiple subtypes.
The overlap between the all subtype PAM list and the clear cell subtype PAM list is 4
CpGs (Table 2.1).
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Table 2.1 Significant PAM analysis CpGs. For each CpG significant by PAM analysis,
the cancer type the CpG was significant for and the gene it was nearest is reported.

Significant
PAM CpG
cg02706881
cg03562120
cg04511534
cg04598121
cg04988978
cg05379350
cg06130787
cg08749917
cg10045881
cg11098259
cg12782180
cg12907644
cg12939547
cg13156411
cg14370448
cg14391855
cg14456683
cg15484375
cg16592658
cg17568996
cg18003231
cg22628873
cg22719623
cg23320056
cg26366091
cg26514492
cg26954174

Cancer
Associated
Type
Gene
general kidney cancer
C21orf123
clear cell renal cell carcinoma
WISP2
both
GGT6
general kidney cancer
PENK
both
MPO
general kidney cancer
GIT1
general kidney cancer
KLK10
general kidney cancer
RTP1
clear cell renal cell carcinoma
CHI3L2
clear cell renal cell carcinoma
AQP9
general kidney cancer
LEP
general kidney cancer
SAA2
VWA7
general kidney cancer
general kidney cancer
PTHR1
clear cell renal cell carcinoma
TBX6
both
RIN1
general kidney cancer
ZIC1
both
SAA1
clear cell renal cell carcinoma
EBI3
general kidney cancer
NFAM1
general kidney cancer
SLC25A18
general kidney cancer
GGT6
general kidney cancer
OPRM1
general kidney cancer
ARHGEF2
clear cell renal cell carcinoma
CHI3L2
general kidney cancer
GPR132
clear cell renal cell carcinoma
NOD2
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Using my data as a training set, I built a logistic regression model from the PAM
diagnostic list capable of discriminating between tumor and benign adjacent tissues.
From the 20 CpG panel from the all subtype PAM list, I selected a model with the
greatest area under the receiver operating characteristic (ROC) curve and an Akaike
Information Criterian (AIC) at a local minima compared to models with one to twenty
CpGs.

This model contained 5 CpGs (cg13156411, cg14456683, cg18003231,

cg12782180, and cg22719623), had a ROC area of 0.991, and a Benjamini and Hochberg
(BH) adjusted p-value of 8.10 X 10-31 for the null hypothesis that the ROC curve area is
0.5 (implying the model would not discriminate between tumor and benign adjacent
tissue). I utilized TCGA data as a validation test set for the predictive model. TCGA has
DNA methylation data available for 732 RCC (ccRCC, pRCC, and ChRCC) tissues and
410 normal kidney tissues. When I apply the 5 CpG model to the TCGA patients, the
ROC area is 0.990 and I correctly predict 87.8% of the normal tissues and 96.2% of the
tumor tissues in the TCGA data (Figure 2.3).
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Figure 2.3 PAM diagnostic panel model for renal cell carcinoma. (A) ROC curve of best
5 CpG model (Benjamini and Hochberg adjusted p-value=8.10 X 10-31) from PAM
diagnostic panel produced via the HAIB/Stanford data (ROC area is 0.991), and applied
to TCGA data (ROC area is 0.990).
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Using the same process with the 11 CpG panel in ccRCC patients, I generated a 4
CpG model (cg04511534, cg11098259, cg14391855, and cg26366091) with a ROC
curve area of 0.990 with a BH adjusted p-value=1.46 X 10-20for the null hypothesis that
the ROC area is 0.5.

I then utilized TCGA(Creighton et al., 2013) ccRCC DNA

methylation data as a test set (218 tumor tissues and 200 normal tissues) for the
predictive model. When I apply my 4 CpG model to the TCGA data set, the AUC=0.972
(Figure 2.4, Panel A) and I correctly identified 91.4% of the tumors and 98.9% of the
benign adjacent tissues. A comparison of the DNA methylation between tumors and
benign adjacent normals in both data sets for these CpGs indicates good agreement. For
example, at cg04511534, I saw no statistical difference between my data and TCGA data,
however the difference between tumor and normal was consistent between the two data
sets (Figure 2.4, Panel B) (See Appendix B, Figure B.1).
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Figure 2.4 PAM diagnostic panel model for ccRCC. (A) ROC curve of best 4 CpG
model (Benjamini and Hochberg adjusted p-value=1.46 X 10-20) from PAM diagnostic
panel produced in the HAIB/Stanford data (ROC area of 0.990) and applied to TCGA
ccRCC data (ROC area of 0.972). (B) DNA methylation at cg04511534, a CpG in the
most predictive HAIB/Stanford model (Mann-Whitney test; Bonferroni adjusted
p-value=0.2524 for HAIB/Stanford normals versus TCGA normals; Bonferroni adjusted
p-value=0.1848 for HAIB/Stanford tumors versus TCGA tumors; Bonferroni adjusted
p-value<0.0001 for HAIB/Stanford normal versus TCGA tumor, Bonferroni adjusted
p-value<0.0001 for HAIB/Stanford tumor versus TCGA normal).
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Figure 2.4 (continued) (C) Expression of GGT6 in TCGA tumor and normal tissue data
(Mann-Whitney test; p-value<0.0001). (D) GGT6 expression versus cg04511534
methylation in TCGA tumor data (linear regression; p-value<0.0001, R2=0.5030).

33

RNA-seq expression data was available for a subset of ccRCC patients in the
TCGA data allowing me to investigate whether the changes in DNA methylation I
observed in the diagnostic panel correlated with expression changes at nearby genes. In 9
of 11 genes, I saw statistically significant differences in the expression of the gene closest
to the significant CpG (Mann-Whitney test, p-value <0.05) in tumor compared to normal
tissue.

For example, cg04511534 is located in the first intron of gamma-

glutamyltransferase 6 (GGT6), a member of the gamma-glutamyltransferase gene family,
and I find expression in this gene is significantly decreased in the TCGA tumors
compared to the TCGA normals (Mann-Whitney, p-value<0.0001) (Figure 2.4, Panel C)
(See Appendix B, Figure B.2). Examining the correlation between cg04511534 DNA
methylation and GGT6 expression in the TCGA data, I found a significant correlation,
following the expected canonical model of increased promoter DNA methylation in the
tumors leading to decreased expression (linear regression, p-value<0.0001; R2=0.503)
(Figure 2.4, Panel D). When examining the correlation between expression and DNA
methylation in the other 10 CpGs from the diagnostic panel and the genes they are near, I
found a range of p-values (0.0001 to 0.8540) and R2 values (0.0001671 to 0.503), with
significant correlation between RNA expression and DNA methylation in 8 of 11 pairs.
These 11 CpGs were all in the promoter region or first intron of a gene, many of
which were biologically interesting. GGT6 has yet to be fully characterized, but it might
be involved in leukotriene synthesis, glutathione metabolism or gamma-glutamyl
transfer, and therefore linked to immune infiltration and inflammation or alterations in
DNA methylation via changing levels of glutathione and methyl group availability
(Heisterkamp, Groffen, Warburton, & Sneddon, 2008; Lertratanangkoon, Wu, Savaraj,
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&Thomas, 1997). In my data set, when I examine the relationship between methylation
at cg04511534 (the CpG in our diagnostic panel in the promoter region of GGT6) and
average methylation across all CpGs in the data set, I find a statistically significant trend
where increasing methylation at cg04511534 correlates with increasing array-wide
methylation (linear regression, p-value<0.0001, R2=0.1988).

When I compare

cg04511534 methylation to the most variant CpGs (standard deviation>0.2, 681 CpGs), I
find the same relationship, but stronger (linear regression, p-value<0.0001; R2=0.5221)
(Data not shown). Other CpGs in the panel were associated with genes related to
immune function as well.

Epstein-Barr Virus-Induced Gene 3 (EBI3) is a subunit of

both IL-27 and IL-35 and is therefore involved in regulating T cell and inflammatory
responses and stimulating tumorigenesis and promoting tumor angiogenesis, respectively
(Carl & Bai, 2008; Long et al., 2013). EBI3 is implicated as a potential diagnosis marker
in Burkitt lymphoma, diffuse large B-cell lymphoma, and lung cancer (Gonin et al.,
2011; Nishino et al., 2011). Myeloperoxidase (MPO) is a heme protein synthesized
during myeloid differentiation and a major neutrophil azurophilic granule component.
Nucleotide-binding oligomerization domain containing 2 (NOD2) is primarily expressed
in peripheral blood leukocytes and gene polymorphisms may be associated with an
altered risk of cancer, including renal cell carcinoma (Kutikhin, 2011). T-box 6 (TBX6)
is a transcription factor involved in regulation of developmental processes, and two of the
11 CpGs are located in the promoter of chitinase-3-like protein 2 (CHI3L2), involved in
cartilage biosynthesis and previously associated with proliferation enhancement
(Miyatake et al., 2013). Two of the associated genes were previously associated with
poor response in cancer patients: aquaporin-9 (AQP9) and ras and rab interactor 1
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(RIN1). AQP9 encodes a protein that allows passage across the cell membrane of noncharged particles, and stimulates urea transport and water permeability and expression of
AQP9 was implicated as an indicator of non-response to chemotherapeutics in colorectal
cancer(Dou et al., 2013).

RIN1 effects RAS signaling in multiple ways and

overexpression is associated with higher grade and poorer prognosis in several cancers,
including gastric adenocarcionma (Yu et al., 2012), hepatocellular carcinoma(He et al.,
2013), melanoma (Fang, Zhao, Tian, & Zhang, 2012), and bladder urothelial carcinoma
(Shan et al., 2012). WNT1 inducible signaling pathway protein 2 (WISP2) may be
involved in malignant transformation and in breast adenocarcinomas, and WISP2
expression is biphasic with high levels associated with non-invasive tumors (Banerjee et
al., 2008). Finally, serum amyloid A1 (SAA1) is highly expressed during inflammation
and has been previously implicated in kidney cancer as a potential Wilms' tumor marker
(Wang et al., 2012), as one of a two protein signature model for prognosis prediction in
metastatic renal cell carcinoma (Vermaat et al., 2010), and as a predictor in fatal outcome
in renal cell carcinoma (Paret, Schön, Szponar, & Kovacs, 2010).

2.3.3 Identification of Differential Copy Number Between Kidney Tumor Tissue
and Benign Adjacent Kidney Tissue
Illumina's Human1M-Duo Beadchip assays over 1.2 million SNPs in the human
genome and can be used to infer CNVs from comparison of fluorescent probe intensities
at each SNP. After quality control, I performed the CNV analysis with 100 patients.
When interrogating genomic regions that differ in copy number between all tumornormal pairs, like others (Beleut et al., 2012), I found all chromosomes were affected by
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copy number events, and most patients had a 3p deletion that contains the VHL gene
locus (Gnarra et al., 1994) (Figure 2.5). To interrogate regions and genes amplified or
deleted in RCC, I used JISTIC (Sanchez-Garcia et al., 2010), an algorithm that identifies
regions of the genome aberrant more often than expected by chance in tumor DNA as
compared to normal DNA. I found 311 peaks with aberrations (159 amplified and 152
deleted, q-value<0.05). While some of these CNVs have been previously reported (Sato
et al., 2013), overwhelmingly this is the first time most of these regions have been
implicated in RCC. In total, I found 3,672 genes with significant CNV (1,758 amplified
and 1914 deleted, q-value<0.05). Not surprisingly, VHL was commonly deleted, as were
genes involved in chromatin remodeling, like SETD2 and PBRM1.

Figure 2.5
patients.

Copy number variation across the genome of 100 renal cell carcinoma
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To understand affected gene functions and pathways, I performed GSEA and GOterm analysis on the amplified and deleted genes separately. GO-terms significantly
associated with genes amplified in the data set were cell adhesion, including homophilic
cell adhesion and cell-cell adhesion, and ion binding, like calcium ion binding. GSEA
significant terms included GPCR function, immune system, cell-cell communication, and
WNT signaling. GO-terms statistically enriched among genes deleted in the patient set,
included citrulline metabolism and chemokines. GSEA of significantly deleted genes
indicated terms associated with GPCRs, the immune system, WNT signaling, VEGF
signaling and metabolism. As with significant terms related to DNA methylation, there
were overlapping terms significant for amplified genes and deleted genes, indicating
differential CNV within the patient set. I also performed JISTIC on only the ccRCC
patient tumor-normal pairs and found similar results when compared to all patients'
results.

2.3.4 Kidney Cancer Recurrence Risk Groups Identified by DNA Methylation
Alterations
To look for patient subgroups in the data set, I used the R package
ConsensusCluster Plus.

Consensus clustering is a method utilizing unsupervised

clustering of subsets of the data over multiple iterations to establish consensus about the
number of groups and group membership in a data set (Wilkerson & Hayes, 2010). I
used the algorithm on all 26,148 CpGs and 99 tumor tissues with k-means clustering from
k=2 to k=10. To ask whether clusters correlate with clinical data, I plotted Kaplan-Meier
curves for the subgroups from each k and determined k=7 had the most significant
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Kaplan-Meier curve (log-rank test, Bonferroni adjusted p-value=0.0003195) (Figure 2.6
panel A and B). To further evaluate the significance of the clusters, I performed a
consensus cluster after shuffling the tissue sample labels in my data, and found no
discernable clustering pattern (K-S test between data and shuffled data distributions,
p-value<0.000001) (see Appendix B, Figure B.3). Cluster 1 (primarily oncocytomas and
chromophobes) and cluster 5 (a mixture of patient subtypes) had no recurrent patients,
and cluster 6 (primarily ccRCC) and cluster 7 (sarcomatoids) had a high rate of
recurrence. Cluster 2 (a mixture of subtypes), cluster 3 (primarily ccRCC), and cluster 4
(a mixture of subtypes) had varying levels of patient recurrence.
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Figure 2.6 Consensus clustering of tumor kidney tissues with DNA methylation changes.
(A) Consensus clustering of 99 tumor kidney tissues by all DNA methylation (26,148
CpGs). (B) Kaplan-Meier curve of patients by consensus cluster group (log-rank test,
Bonferroni adjusted p-value=0.0003195).
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Figure 2.6 (continued) (C) Average DNA methylation per patient across all CpGs
(26,148) and across the most variant CpGs (standard deviation >0.2, 681 CpGs) by
cluster group (Kruskal-Wallis, p-value<0.0001). (D) Number of genes with an
amplification or deletion event per patient by consensus cluster group (Kruskal-Wallis,
p-value=0.0031).
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After establishing clusters, I examined the level of DNA methylation across all of
the CpGs and across the most variant CpGs within each cluster and between each cluster
(Figure 2.6, panel C). I found a significant difference across the seven clusters, where
cluster 1 had the lowest average DNA methylation and cluster 7 had the highest average
DNA methylation (Kruskal-Wallis test, p-value<0.0001). When I examine the average
DNA methylation across only the most variant CpGs (standard deviation>0.2, 681
CpGs), the trend in increasing DNA methylation across clusters is magnified, but cluster
6 had a higher average DNA methylation than cluster 7. I also looked at the frequency of
genes with a copy number event per patient in each cluster and found a significant trend,
most notably where cluster 1 had a higher incidence of chromosomal instability than the
other clusters (Kruskal-Wallis, p-value=0.0031) (Figure 2.6, panel D).

I built upon

previous work showing ccRCC clusters with more DNA methylation have poorer
prognosis(Arai et al., 2012), but this is the first study utilizing a consensus algorithm to
establish clusters and examine gross CNV within them as well.
To understand the potential biological differences between these clusters, I
determined the CpGs significantly associated with each of the seven clusters by
performing a linear regression analysis of all 26,148 CpGs with patient gender and grade
as covariates. I found 9,584 CpGs significant for at least one of the clusters (FDR<0.05).
I performed GSEA and GO-term analysis with genes nearest those CpGs significant by
cluster.

Genes associated with these CpGs were enriched for GO-terms related to

immune response, the GPCR pathway, signaling activities, and the plasma membrane.
GSEA indicated differential terms across cluster subgroups related to GPCR-associated
terms, T cell-associated terms (including leukocyte transendothelial migration),
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interferon-associated terms, and other immune-related terms (ex. IL-10, IL-7, IL-2).
Notably, this provides an explanation for my results indicating similar GO- and GSEA
terms significant for both increased and decreased DNA methylation in tumors than
benign adjacent normals, and demonstrates a method for identifying subgroups of RCC
with both differing recurrence incidence and unique DNA methylation profiles.
Consensus clustering was performed on only the ccRCC patients and similar results were
seen (see Appendix G).

2.3.5

Kidney Cancer Recurrence Risk Increases with Array-Wide DNA
Methylation Increase and Has a Non-Monotonic Relationship with Copy
Number Instability
I extended the consensus cluster analysis of the average CpG methylation and

copy number change across clusters to examine hazard ratios as CpG methylation
increases and frequency of genes with CNVs increases across patients (Figure 2.7 panel
A and B). As average DNA methylation across the most variant CpGs increased, patient
recurrence incidence increased in a roughly linear fashion. When the frequency of genes
with CNVs increased across patients, there was a non-monotonic relationship where
patient recurrence incidence increased linearly for low and mid frequency gene CNV, but
patients with the highest frequency gene CNV had no recurrence. Figure 2.7 Panel C
depicts the relationship between DNA methylation, CNV, and incidence of recurrence
across the data set. A similar trend is seen for only ccRCC patients (data not shown).
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Figure 2.7 The relationship between incidence of recurrence and DNA methylation is
linear, while the relationship between incidence of recurrence and copy number change is
non-monotonic. (A) Hazard ratios by increasing most variant CpG average methylation
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(54.5%, 22.1%, 16.9%, and 6.5% of patients from low to high DNA methylation,
respectively). (B) Hazard ratios by increasing number of genes with copy number
changes (44.1%, 24.7%, 18.2%, and 13.0% of patients from low CNV to high CNV,
respectively) (Confidence intervals are not meaningful in the 4000+ group because no
patients were recurrent). (C) Proportion of patients in each DNA methylation and copy
number group that recurred.

2.4 Discussion
Early diagnosis of RCC is difficult and treatment at later stages is often
ineffective (Rini et al., 2009). Patients who are diagnosed at an early stage followed by
resection have a high 5-year survival rate, but once the cancer has metastasized,
treatments are ineffective and carry adverse side-effects. Other studies have shown the
potential of measuring promoter DNA methylation in urine and serum DNA of RCC
patients (Battagli et al., 2003; Hoque et al., 2004), but they examined a small set of
candidate genes. By examining genome-wide DNA methylation, I found over 500 CpGs
more discriminatory between tumor and normal tissue than the most significant CpG I
assayed in these reported candidate genes.

I developed a panel of 20 CpGs that

discriminate between multiple subtypes of kidney tumor tissue from normal tissue, as
well as a panel of 11 CpGs that discriminate between ccRCC tumor tissue and normal
tissue, in both my data set and the independent TCGA data set. Because of the high
sensitivity and specificity of the biomarkers in both data sets, these panels are prime
candidates for future studies to develop a clinical test for early detection of RCC. These
biomarkers might also be useful to discriminate between small benign and small
malignant lesions and to follow patients after resection for early detection of recurrence.
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These candidate biomarkers were all in the promoter region or first intron of a
gene, many of which were biologically interesting. For example, GGT6 has yet to be
fully characterized, but current evidence suggests involvement in leukotriene synthesis,
glutathione metabolism, or gamma-glutamyl transfer, and therefore linked to immune
infiltration and inflammation or alterations in DNA methylation via changing levels of
glutathione and methyl group availability (Heisterkamp et al., 2008; Lertratanangkoon et
al., 1997).

In this data set, I found a significant correlation between increasing DNA

methylation at cg04511534 (in the first intron of GGT6) and increasing array-wide DNA
methylation (linear regression; p-value<0.0001, R2=0.1988). (Data not shown). Other
CpGs in the panel were associated with genes related to immune function, such as
regulating T cell and inflammatory responses and stimulating tumorigenesis and
promoting tumor angiogenesis (EBI3) (Carl & Bai, 2008; Long et al., 2013), and with
genes implicated in cancer prognosis (AQP9, RIN1) (Dou et al., 2013; Fang et al., 2012;
He et al., 2013; Shan et al., 2012; Yu et al., 2012). Interestingly, one of the candidate
biomarkers, serum amyloid A1 (SAA1) has been previously implicated in RCC. SAA1 is
highly expressed during inflammation and has been identified as a potential Wilms'
tumor marker (Wang et al., 2012), as one of a two protein signature model for prognosis
prediction in metastatic renal cell carcinoma (Vermaat et al., 2010), and as a predictor in
fatal outcome in renal cell carcinoma (Paret et al., 2010).
Previous studies indicated that chromosomal instability and DNA methylation can
influence patient response to different therapies, therefore this work suggests future
directions for study and treatment in RCC (Lee et al., 2011; McClelland et al., 2009;
Toyota et al., 2009). In particular, the consensus cluster results uncovered varying DNA
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methylation in pathways related to GPCRs, immune response, and cell metabolism.
Also, RCC is generally non-responsive to traditional radiation therapy and chemotherapy,
but recent clinical drug trials indicated a subset of patients responded well to particular
immunotherapies (particularly targeting T cell function) (Brahmer et al., 2012; Hudes et
al., 2007; Motzer et al., 2012; Yang et al., 2007). Altered DNA methylation patterns
could indicate changing cell type and suggest potential immune infiltration and
inflammation response in the tumor microenvironment related to patient response. The
importance of genomics for informing not only new drug targets, but which drugs to use
in which patients, is invaluable. Future studies combining genome-wide analysis with
drug trials in RCC may elucidate which patients will respond to particular treatment
regimens.
Recently, the linear trend between increasing promoter DNA methylation and
increasing stage and grade in ccRCC was reported (Creighton et al., 2013), and I show
this trend in relation to recurrence incidence and copy number variation. The nonmonotonic relationship I observed between recurrence incidence and gene copy number
variation has also been shown in ER-/HER2- breast cancer, ovarian cancer, squamous
non-small cell lung cancer, and gastric cancer(Birkbak et al., 2011), but has not been
reported in kidney cancer. The relationship between variable responses to therapeutics
and increased DNA methylation or increased copy number instability in cancers, makes
this finding in RCC valuable. Furthermore, recent studies indicate a connection between
the immune system and chromosomal instability (Senovilla et al., 2012), where
immunosurveillance selects against hyperploidy in cancer. Future studies are needed to
determine if this mechanism might be at play in a subset of RCC patients.
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It is likely with higher resolution DNA methylation or CNV assays additional
CpGs and CNVs of interest would be uncovered and prospectively may offer even
greater resolution about the relationship between increased DNA methylation, copy
number variation, and recurrence.

Also, examination of genome-wide expression

changes in conjunction with DNA methylation and copy number changes would likely
yield new insights, as suggested by the examination of TCGA expression data in
relationship to nearby DNA methylation of the diagnostic panel. Combining all of these
data types in RCC with immune cell data, particularly of T cells, could also be
invaluable.

Improving the diagnostics of RCC and informing novel drug targets is

paramount for improving patient survival and quality of life. Analysis and integration
across multiple data types in independent cohorts is likely to increase understanding and
direct new research not only in RCC, but cancer in general.
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CHAPTER 3

DNA METHYLATION AND COPY NUMBER PROFILES OF HISTOLOGICAL
SUBTYPES OF RENAL CELL CARCINOMA

3.1 Introduction
RCC is the tenth most common cancer (Ferlay et al., 2010), and is composed of
many subtypes based mostly on histology. These different subtypes arise from different
parts of the nephron, and are associated with varying survival and recurrence rates. In
recent years, the World Health Organization (WHO) has included genetic alterations as
distinguishing factors for these subtypes. Current WHO guidelines recognize almost 50
distinct renal neoplasms and there is an on-going effort to characterize both the clinical
and genetic features of these emerging subtypes(Lopez-Beltran et al., 2009, 2013). The
most common, clear cell RCC (ccRCC), arises from the proximal convoluted tubule in
the kidney, affects 75% of RCC patients, and is characterized by loss of chromosome 3p
and inactivation of VHL. The second most common subtype is papillary RCC (pRCC),
accounting for 10 to 15% of cases, and is characterized by amplification of chromosomes
7 and 17.

Additional subtypes are less common and include chromophobe RCC

(ChRCC), which is characterized by many chromosomal monosomies, oncotytomas, a
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benign tumor with a largely diploid genome, and the newly characterized clear cell
papillary RCC (CCPRCC), which lacks the chromosomal alterations seen in ccRCC or
pRCC, and is associated with low grade (Hagenkord et al., 2011; Srigley & Delahunt,
2009).
Previous studies have identified CNV or DNA methylation differences between
some RCC subtypes, but no study has examined both genomic analyses in the same
cohort (Ellinger et al., 2011; Hagenkord et al., 2011; Monzon et al., 2008). Additionally,
little is known about CCPRCC. Because these subtypes arise from different cells in the
kidney, respond differently to chemotherapies, and are associated with different survival
rates, understanding more about the etiology of these diseases and the different genetic
variation between them could inform clinical practice.
In this study, I profiled DNA methylation and CNVs across 87 RCC patients
diagnosed with one of five RCC subtypes: ccRCC, pRCC, ChRCC, CCPRCC, and
oncocytomas.

This integrated analysis of kidney tumor tissue identified molecular

changes associated with various RCC subtypes, establishing unique DNA methylation
and CNV patterns capable of differentiating these subtypes, as well as the first
characterization of both data types in CCPRCC.

3.2 Methods
Rick Myers, Devin Absher, and Jim Brooks assisted with planning experiments
and analyzing data. I worked with Devin Absher and his lab to perform the DNA
methylation and copy number variation assays.
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Preti Jain performed ComBat

normalization of the DNA methylation data. Todd Burwell contributed to the statistical
analysis.

3.2.1 Tissue Collection and Preparation
Kidney tissues used in this study were collected at Stanford University with
patient's informed consent under IRB-approved protocols. Sections were examined by a
pathologist and clinical information associated with each patient is summarized in
Appendix A. DNA was isolated from tissues using the QIAGEN AllPrep DNA kit
(QIAGEN) following the manufacturer's protocol.

For this study, only patients

diagnosed with a single, specific subtype were included, and only subtypes with at least
three patients were included. These subtypes consisted of ccRCC (n=63), pRCC (n=7),
ChRCC (n=9), CCPRCC (n=3), and oncocytoma (n=4).

3.2.2

Sodium Bisulfite Conversion and Illumina Infinium HumanMethylation27
Assay
Sodium bisulfite conversion of gDNA was performed using the EZ-96 DNA

Methylation Kit (Deep-well format, ZymoResearch) with the alternative incubation
protocol for the Illumina Infinium Methylation Assay, as described by the manufacturer.
Five hundred nanograms of sodium bisulfite-converted gDNA from patient tissues was
assayed by Infinium HumanMethylation27 RevB Beadchip Kits (Illumina) per the
manufacturer's protocol.
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3.2.3

Beta Score Calculations, Filtering, and Batch Normalization of DNA
Methylation Data
HumanMethylation27 array results were analyzed using Illumina BeadStudio

software with the Methylation Module v3.2. All negative beta scores were converted to
zero and beta scores with an associated detection p-value>0.01 were converted to "NA"
and filtered from analysis. To correct any array-by-array variation, all missing values
were imputed with KNN Impute, followed by array batch normalization using the
ComBat R-package (Johnson et al., 2007). Previously imputed values were converted
back to "NA" for all further analyses. CpGs with "NA" in greater than 10% of samples
were removed from the data set.

As previously reported, I removed CpGs with

questionable mapping or CpGs that included a SNP of >3% minor allele frequency within
15 bp of the assayed CpG to avoid potential variation in probe hybridization (Kobayashi
et al., 2011).

After quality control and filtering, I had 96 patients with 26,148 CpGs

assayed in both kidney tumor and benign adjacent tissues.

3.2.4 Illumina Human 1M-Duo Assay and JISTIC Analysis
Two hundred and fifty nanograms of gDNA from patients were assayed by
Infinium Human1M-Duo Beadchip Kits (Illumina). The assay was performed using the
protocol as described by the manufacturer. After quality control, I had 100 patients with
both kidney tumor and benign adjacent normal data. Log R ratios were obtained from
BeadStudio. Copy number variation analysis was performed between the kidney tumor
data and the paired benign adjacent normal data utilizing the focal (limited peel-off)
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algorithm in the Java implementation of JISTIC per the manual's instructions (SanchezGarcia et al., 2010).

3.2.5 Linear Regression Analysis
For the regression analysis I used RStudio (version 0.97.551) in R (version 3.0.0).
The lm command was used for the linear regression of the methylation changes between
subtypes with patient age as a covariate.

Model p-values were adjusted for multiple

hypothesis testing utilizing the Benjamini and Hochberg algorithm and significant CpGs
have an adjusted p-value <0.05 (Foulkes, 2010). The lm command was also used for the
linear regression of the CNV changes between subtypes utilizing the JISTIC limited
algorithm adjusted CNV gene values with patient age as a covariate. Model p-values
were adjusted for multiple hypothesis testing utilizing the Benjamini and Hochberg
algorithm and significant genes have an adjusted p-value <0.05 (Foulkes, 2010).

3.2.6 Hierarchical Clustering
Prior to hierarchical clustering, beta scores were mean-centered. Hierarchical
clustering of the DNA methylation data by both gene and patient was done using Cluster
3.0 with average linkage (Eisen et al., 1998). Hierarchical clustering of the CNV data by
both gene and patient was also done using Cluster 3.0 with average linkage.
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3.3 Results

3.3.1 DNA Methylation Alterations Identify Histological Subtypes of Renal Cell
Carcinoma
To identify CpGs carrying subtype-specific DNA methylation, I performed linear
regression models including age as a fixed effect. When I analyzed all CpGs and selected
patients with these models, 6,609 CpGs were significantly different between the RCC
subtypes (FDR<0.05). I performed hierarchical clustering by patient and CpG for these
results (Figure 3.1) and observed all of the ChRCC, CCPRCC, and oncocytoma cases
clustered together, respectively, most of the ccRCC patients clustered together (96.8%),
and 71.4% of the pRCC cases clustered together. Notably, the oncocytomas and the
ChRCCs had very similar DNA methylation patterns and while profiles with like
histologies clustered together, the two subtypes clustered next to one another under the
same branch, similar to previous reports (Arai et al., 2011).
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Figure 3.1 Hierarchical clustering of ccRCC, pRCC, ChRCC, oncocytoma, and
CCPRCC tumor tissues (columns) by significant subtype DNA methylation changes
(rows). Clustering is by both tissue and CpG of 87 kidney tumor tissues with linear
regression model significant CpGs (FDR<0.05; 6,609 CpGs).
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When individual subtypes were examined against all other patients by linear
regression analysis with age as a covariate, I found 20.04% of all CpGs assayed (5,239
CpGs) were associated with ccRCC, 10.70% with ChRCC (2,798 CpGs), 2.67% with
oncocytoma (698 CpGs), 0.15% with CCPRCC (38 CpGs), and 2.13% with pRCC (557
CpGs), demonstrating vast differences in DNA methylation between subtypes as
previously reported (Arai et al., 2011, 2012; Costa et al., 2007; Slater et al., 2013).
Additionally, I identified 2,748 CpGs with differential DNA methylation between
oncocytomas and ChRCCs that have potential as molecular discriminators. For example,
cg11826486 in the promoter region of thymosin-like 3 (TMSL3, a pseudogene on
chromosome 4q22.1), has decreased DNA methylation in oncocytomas compared to
ChRCCs (Figure 3.2).

A recent report examining serum peptide changes between

malignant and benign RCC found this protein had increased expression in malignant
compared to benign tumors (Gianazza et al., 2012). While the canonical model is DNA
methylation in the promoter region results in decreased RNA expression and thus
decreased protein expression, given the small number of tumors in this study and the
serum peptide study, as well as other variables in expression regulation, future studies are
needed to clarify this finding.
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Figure 3.2 DNA methylation at cg11826486 (in the promoter of TMSL3) differentiates
oncocytoma tumors from ChRCC tumors.

To my knowledge this is the first study of DNA methylation changes in
CCPRCC. While there are only three CCPRCC tumors, examination of the 38 CpGs
with DNA methylation specific to this subtype reveals two of the three tumors
consistently have reduced DNA methylation compared to other RCC tumors (Figure 3.3).
For example, the most significant CpG, cg01091565 (BH adjusted p-value=4.35 X 10-07),
is in the promoter region of mesoderm posterior 1 homolog (MESP1) and has
significantly decreased methylation in two of the three CCPRCC patients. MESP1 is a
crucial transcription factor in the differentiation of cardiac progenitors and has not
previously been implicated in cancer (Islas et al., 2012).
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Figure 3.3 DNA methylation at cg01091565 (in the promoter region of MESP1) in
CCPRCC tumors and other RCC tumors(BH adjusted p-value=4.35 X 10-07).

3.3.2

Copy Number Variation Distinguishes Histological Subtypes of Renal Cell
Carcinoma
To identify genes with subtype-specific CNV changes, I performed linear

regression models including age as a fixed effect and adjusted gene averages from
JISTIC. When I analyzed the genes significant by subtype, I found there were 15,512
genes significant between all subtypes (FDR<0.05). I performed hierarchical clustering
by patient and gene for these results (Figure 3.4) and observed the majority of pRCCs
(71.4%), ccRCCs (82.5%), and ChRCCs (77.8%) clustered together, respectively, while
oncotytomas and CCPRCCs were scattered throughout the cluster tree. While ChRCCs
and oncocytomas had very similar DNA methylation profiles, ChRCCs had gross CNV
changes resulting in a distinct profile that differentiated ChRCC from oncocytoma
patients.
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Figure 3.4 Hierarchical clustering of ccRCC, pRCC, ChRCC, oncocytoma, and
CCPRCC kidney tumor tissues (columns) with significant subtype CNV gene changes
(rows). Clustering is by both tissue and gene of 87 kidney tumor tissues with linear
regression model significant genes (FDR<0.05; 15,512genes).
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When individual subtypes were examined against all other patients by linear
regression model as previously described, 85.0% of genes were significant for ChRCCs
(16,342 genes), 65.7% of genes were significant for ccRCCs (12,637 genes), 16.5%of
genes were significant for pRCCs (3,166 genes), and no genes were significant for
oncocytomas or CCPRCCs. This is not surprising considering the widespread CNV
changes in ChRCC and the very low level of CNVs seen in both CCPRCC and
oncocytomas (Figure 3.5). In ccRCC, the 3p arm is widely deleted and therefore so is
VHL, as well as SET domain containing 2 (SETD2), and polybromo 1 (PBRM1), both
involved in chromatin remodeling and previously implicated in ccRCC (Creighton et al.,
2013; Dalgliesh et al., 2010; Varela et al., 2011).

As previously reported, I see

widespread changes in ChRCCs, mostly diploid oncocytomas, and chromosome 7
amplifications in pRCC (Hagenkord et al., 2011; Monzon et al., 2008).
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Figure 3.5 Genome-wide copy number profiles by renal cell carcinoma subtype.

3.3.3

Global DNA Methylation and Copy Number Variation Patterns Differ
Between Renal Cell Carcinoma Histological Subtypes
Next I examined how average array-wide DNA methylation and CNV changed

between subtypes.

Examining array-wide DNA methylation alterations between

subtypes, I found significant differences.

Notably, there was an increase in DNA

methylation in pRCC tumors compared to other subtypes (Figure 3.6, panel A), in line
with a previous report examining DNA methylation of candidate genes in CpG islands,
suggesting hypermethylation could be a hallmark of pRCC (Ellinger et al., 2011).
Restricting analysis to the average of only the most variant CpGs, I found this trend was
exaggerated (Figure 3.6, panel B).
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Figure 3.6 Average DNA methylation levels by RCC subtype. (A) Average DNA
methylation per patient across all CpGs (26,148; Kruskal-Wallis, p-value=0.0044) by
subtype. (B) Average DNA methylation per patient across the most variant CpGs
(standard deviation >0.2, 681 CpGs; Kruskal-Wallis, p-value<0.0001) by subtype.

Likewise, inspecting the number of genes per patient with a CNV event by
subtype, I found ChRCC had gross CNV, while oncocytomas and CCPRCC had almost
no genes with a CNV event (Figure 3.7). Previous reports have noted the lack of CNV in
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oncocytomas and widespread CNV in ChRCC(Tan et al., 2010), but here I can compare
these levels with DNA methylation levels and with ccRCC, pRCC, and CCPRCC
subtypes (Figure 3.8).

Figure 3.7 Number of genes with an amplification or deletion event per patient by
subtype (Kruskal-Wallis, p-value=0.0024).
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Figure 3.8 Comparison of global copy number variation and DNA methylation by
subtype.

3.4 Discussion
RCC

subtypes

are known to

have differing etiologies, response to

chemotherapies, and survival rates (Lopez-Beltran et al., 2009, 2013). An increased
understanding of the genetic variation existing between these subtypes could inform
clinical care and aide with diagnosis. While WHO has recently begun including genetic
variation as diagnostic criteria in addition to histological features, DNA methylation
alterations have not been utilized for diagnosis. Additionally, newly identified subtypes,
like CCPRCC, have not been examined for genome-wide DNA methylation and CNV
changes at all, let alone in relation to other subtypes.
I found widespread DNA methylation and CNV differences between the five
RCC subtypes studied: ccRCC, ChRCC, pRCC, oncocytoma, and CCPRCC. I identified
CpGs differentially methylated between all five subtypes and genes with altered CNV
specific to ccRCC, pRCC, and ChRCC. Global CNV and DNA methylation changes also
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varied between the subtypes. Notably, I can expand upon the observation by Ellinger, et
al. indicating increasing DNA methylation in candidate genes as a hallmark of pRCC by
showing this increase in methylation expands past their candidate genes (Ellinger et al.,
2011). Overall, I found widespread DNA methylation in all five subtypes and identified
DNA methylation alterations between them.
Because of the morphological similarities between oncocytomas and ChRCC,
proper identification by pathologists can be challenging. I can confirm previous findings
suggesting CNV in ChRCC (Monzon et al., 2008), but not oncocytomas, and suggesting
that while the DNA methylation profiles of the two subtypes are very similar, there are
still significant DNA methylation differences (Arai et al., 2011). Specifically, I found
2,748 CpGs that are potential molecular discriminators between the two subtypes.
Oncocytomas are a benign tumor, but ChRCC, despite having higher survival rates than
ccRCC, is a malignant tumor and there is no effective treatment aside from surgery
(Linehan, Srinivasan, & Garcia, 2013; Stec, Grala, Maczewski, Bodnar, & Szczylik,
2009).

The ability to correctly distinguish ChRCCs from oncocytomas and inform

potential drug targets for ChRCC is crucial for patient care.
To my knowledge, this is the first study examining global DNA methylation and
CNV changes in CCPRCC. As others have reported (Aydin et al., 2010; Park, Lee, Suh,
& Moon, 2012; Srigley & Delahunt, 2009), despite morphological features of both
ccRCC and pRCC, I did not see the hallmark chromosome 3p deletion of ccRCC in
CCPRCC.

However, as in pRCC, I saw chromosome 7p amplification, but not

chromosome 17 amplification.

Additionally, I saw low level CNV, like in benign

65

oncocytomas, and I identified 38 CpGs with DNA methylation alterations specific to
CCPRCC.
Future studies including additional RCC subtypes and examining RNA expression
may be useful for characterizing genetic variation of these tumors, understanding the vast
differences in survival and recurrence rates, and identifying novel chemotherapeutic
targets. This study demonstrates the power of integrating multiple genomic data sets in
the investigation of genetic variation among RCC subtypes.
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CHAPTER 4

MICROSATELLITE INSTABILITY IN RENAL CELL CARCINOMA

4.1 Introduction
Renal cell carcinoma (RCC) accounts for 4% of all adult cancer, constituting
almost 60,000 new cases in the United States per year (Ferlay et al., 2010). DNA
sequencing studies in RCC have demonstrated a profuse genetic heterogeneity between
patients that has yet to be fully characterized (Creighton et al., 2013; Dalgliesh et al.,
2010; Gerlinger et al., 2012; Varela et al., 2011), and it is likely additional pathways are
involved in the etiology and progression of RCC.
Mismatch repair (MMR) genes are responsible for the detection and repair of
nucleotide mismatches during DNA replication caused by polymerase slippage (Imai &
Yamamoto, 2008). These errors are more abundant in repetitive regions of the genome,
like microsatellite sequences (2 to 6 repeating base pairs), and can lead to sequences of
abnormal length in a phenomenon known as microsatellite instability (MSI) (Thibodeau,
Bren, & Schaid, 1993).

When MMR pathway genes are mutated or epigenetically

silenced, uncorrected expansions and deletions occur, leading to MSI (Migliore, Migheli,
Spisni, & Coppedè, 2011). MSI that occurs in or near a gene can induce frameshift
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mutations in tumor suppressors, encouraging tumorigenesis.

This discovery and

characterization of MSI supplied early and convincing evidence for mutator phenotypes
in cancer (Perucho, 2003) and provided insight into molecularly, pathologically, and
clinically different subtypes of colorectal (Colussi, Brandi, Bazzoli, & Ricciardiello,
2013), gastric (Kim et al., 2013; Lee et al., 2013), prostate (Jarzen, Diamanduros, &
Scarpinato, 2013), endometrial (Metcalf & Spurdle, 2013; Nelson et al., 2013), and other
cancers (Karamurzin et al., 2012).
MSI has been most extensively characterized in colorectal cancer (CRC) where it
accounts for 15% of cases, most caused by methylation of the MLH1 promoter region
(Umar et al., 2004).

In CRC, integrative genomic analyses reveal two large subtypes--

onewith gross chromosomal instability and the other with gross DNA methylation
changes in CpG islands. MSI CRC is a subset of the latter (Cancer Genome Atlas
Network, 2012; Wong, Hawkins, & Ward, 2007), and is tested for with the Bethesda
Panel (Boland et al., 1998; Umar et al., 2004).

This panel targets five microsatellite

regions and depending on the percentage of regions demonstrating MSI, the patient is
classified as microsatellite stable (MSS), microsatellite instable-low (MSI-L), or
microsatellite instable-high (MSI-H). MSI CRC tumors often present with increased
mucin secretion, poor differentiation, increased lymphocytic infiltration, and are more
likely to be located in the proximal colon (Migliore et al., 2011; Thibodeau et al., 1993).
About 3% of CRC is a hereditary form of MSI CRC, known as hereditary nonpolyposis colorectal cancer (HNPCC), caused by Lynch syndrome. Lynch syndrome
predisposes patients to cancer because of germline mutation in an MMR gene (Imai &
Yamamoto, 2008; Lynch et al., 2009). Hereditary and sporadic MSI CRC have similar
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clinical features, but sporadic MSI CRC tend to have more mucin secretion, poorer
differentiation, and increased tumor heterogeneity, while hereditary MSI CRC is
associated with more lymphatic infiltration.

Studies have resulted in conflicting

conclusions on the responsiveness of MSI-H patients to chemotherapeutics like 5fluorouracil and irinotecan with results ranging from beneficial, to no response, to
detrimental (Devaud & Gallinger, 2013).

However, most of these studies were

retrospective, no consistent method was used to detect MSI or assign MSI-H status, and
tumor stage was not carefully controlled.
Lynch syndrome patients have previously been reported to develop RCC tumors
(Geary et al., 2008; Pedroni et al., 2013). While studies examining the prevalence of MSI
in RCC or characterizing the expression of MMR proteins have been done, they have
resulted in mixed conclusions likely reflective of the mixed experimental conditions of
the studies (Altavilla et al., 2010; Chen et al., 2000; Deguchi et al., 2003; Diakoumis et
al., 1998; Goessl et al., 1998; Kanomata, Eble, & Halling, 1998; Leach et al., 2002; Shin
et al., 2000; Stoehr et al., 2012; Thrash-Bingham et al., 1995; Willers et al., 1996). These
studies did not have proper normal controls for MSI determination, a consistent MSI
panel, a consistent metric for assigning MSI-H, or lacked complete denaturing
electrophoresis conditions. Also, no study to date has investigated MSI in RCC while
examining global CNV and DNA methylation, as well as potential CNV and DNA
methylation alterations in MMR genes.
In this study, I profiled MSI in 101 RCC patients with the Bethesda Panel and
compared those results with both global DNA methylation and CNV levels, as well as
DNA methylation and CNV alterations in MMR genes. This integrated analysis was the
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first of its kind, and while it echoed MSI at levels in RCC compatible with previous
reports (Altavilla et al., 2010; Stoehr et al., 2012) and I found widespread DNA
methylation and CNV changes in MMR genes, I did not find any correlation between
CNV or DNA methylation changes and MSI in RCC patients.

4.2 Methods
Rick Myers, Devin Absher, and Jim Brooks assisted with planning experiments
and analyzing data. I worked with Devin Absher and his lab to perform the DNA
methylation and copy number variation assays.

Preti Jain performed ComBat

normalization of the DNA methylation data. Todd Burwell contributed to the statistical
analysis.

4.2.1 Tissue Collection and Preparation
Kidney tissues used in this study were collected at Stanford University with
patient's informed consent under IRB-approved protocols. Sections were examined by a
pathologist and clinical information associated with each patient is summarized in
Appendix A. DNA was isolated from tissues using the QIAGEN AllPrep DNA kit
(QIAGEN) following the manufacturer's protocol. gDNA concentration was determined
by dsDNA HS Assay on a Qubit 2.0 Fluorometer (Life Technologies) and diluted in TE
buffer to a final concentration of 3.8 ng/ul.
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4.2.2 Microsatellite Instability Evaluation
To investigate MSI, PCR was performed with primers targeting the Bethesda
panel as described in Table 4.1, and OneTaq 2X Standard Reaction Buffer (New England
Biolabs) under the following conditions : 94 ͦC (30 seconds);30 cycles of 94 ͦC (15
seconds), 65 ͦC (30 seconds), 68 ͦC (30 seconds); and a final extension at

68 ͦC (5

minutes). BAT-25 and BAT-26 were amplified in the same reaction, D2S123 and
D17S250 were amplified in the same reaction, and D5S346 was amplified alone.

Table 4.1 Microsatellite instability PCR targets.

PCR
Target

PCR
Primers

D2S123

5'-AAAACAGGATGCCTGCCTTTAACA-3'
5'-GCTCTTTTGAATTGGAGGGGACTT-3'
D5S346 5'-TGGTTTCCATTGTAGCATCTTGACA-3'
5'-TTGGCCTGGTTGTTTCCGTAGTAT-3'
BAT-25 5'-GCCTCCAAGAATGTAAGTGGGAGT-3'
5'-CCAAAGAGACAGCAGTTGGAACAT-3'
BAT-26 5'-TCAGAGCCCTTAACCTTTTTCAGG-3'
5'-ACTCTGGCCTAGGGAACAAGTGAG-3'
D17S250 5'-GGATTACAGGCATGAGCCACTCAG-3'
5'GGATTTTGGTAAGTCAAGCATGCACA-3'

Expected
Mono- or
Product Dinucleotide
Size (bp)
Repeat
230
Di247

Di-

196

Mono-

258

Mono-

344

Di-

Denaturing (5.6M urea, 32% formamide) polyacrylamide (10%) gels (16cm X
20cm X 1mm) were pre-run for 30 minutes. 5 ul of PCR product was denatured for 5
minutes at 95°C in RNA loading dye (New England Biolabs) and cooled on ice for 3
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minutes before loading. Gels were run for 9 hours at 300 Volts in 1X TBE and then
washed in 1X TBE for 10 minutes. After washing, gels were stained with Sybr Gold
(Invitrogen) for 20 minutes before imaging.

Tumor PCR products that differed in size

from the PCR product of the same loci in the adjacent benign kidney tissue were
considered to have microsatellite instability at that loci.

4.2.3

Sodium Bisulfite Conversion and Illumina Infinium HumanMethylation27
Assay
Sodium bisulfite conversion of gDNA was performed using the EZ-96 DNA

Methylation Kit (Deep-well format, ZymoResearch) with the alternative incubation
protocol for the Illumina Infinium Methylation Assay, as described by the manufacturer.
Five hundred nanograms of sodium bisulfite-converted gDNA from patient samples was
assayed by Infinium HumanMethylation27 RevB Beadchip Kits (Illumina) per the
manufacturer's protocol.

4.2.4

Beta Score Calculations, Filtering, and Batch Normalization of DNA
Methylation Data
HumanMethylation27 array results were analyzed using Illumina BeadStudio

software with the Methylation Module v3.2. All negative beta scores were converted to a
zero and beta scores with an associated detection p-value>0.01 were converted to "NA"
and filtered from analysis. To correct any array-by-array variation, all missing values
were imputed with KNN Impute, followed by array batch normalization using the
ComBat R-package(Johnson et al., 2007). Previously imputed values were converted
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back to "NA" for all further analyses. CpGs with "NA" in greater than 10% of samples
were removed from the data set.

As previously reported, I removed CpGs with

questionable mapping or CpGs that included a SNP of >3% minor allele frequency within
15 bp of the assayed CpG to avoid potential variation in probe hybridization(Kobayashi
et al., 2011).

After quality control and filtering, I had 96 patients with 26,148 CpGs

assayed in both kidney tumor and benign adjacent tissues.

4.2.5 Illumina Human 1M-Duo Assay and JISTIC Analysis
Two hundred and fifty nanograms of gDNA from patient samples were assayed
by Infinium Human1M-Duo Beadchip Kits (Illumina). The assay was performed using
the protocol as described by the manufacturer. After quality control, I had 100 patients
with both kidney tumor and benign adjacent normal data. Log R ratios were obtained
from BeadStudio. Copy number variation analysis was performed between the kidney
tumor data and the paired benign adjacent normal data utilizing the focal (limited peeloff)

algorithm

in

the

Java

implementation

of

JISTIC

per

the

manual's

instructions(Sanchez-Garcia et al., 2010).

4.2.6 Linear Regression Analysis
For the regression analysis I used RStudio (version 0.97.551) in R (version 3.0.0).
The lm command was used for the linear regression of the methylation changes between
MSI-H and MSS patients with patient gender and age as covariates. The regression
model has p-values adjusted for multiple hypothesis testing utilizing the Benjamini and
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Hochberg algorithm and significant CpGs have an adjusted p-value <0.05 (Foulkes,
2010).

4.2.7 Consensus Clustering
Consensus clustering was performed on significant linear mixed model MMR
gene associated CpGs (Chapter 2) using the ConsensusCluster Plus package in R with kmeans

clustering

from

k=2

to

k=10

and

Euclidean

distance

for

1000

repetitions(Wilkerson & Hayes, 2010).

4.3 Results

4.3.1

Mismatch Repair Genes Have Significant DNA Methylation Alterations
and Copy Number Variation in Renal Cell Carcinoma Patients
Examination of the linear mixed effects model results (Chapter 2.3.1) identifying

CpGs with tumor-specific aberrant DNA methylation revealed significant alterations in
ten genes (MLH1, PMS2, MSH3, MSH4, LIG1, POLD1, RPA3, EXO1, POLD3, and
POLD4) of the MMR pathway. ConsensusClustering(Wilkerson & Hayes, 2010) of
these CpGs in all RCC patient tumor tissue revealed two distinct groups at k=2 (Figure
4.1), suggesting two different patterns of MMR DNA methylation based solely on
significant CpGs in MMR genes. Examination of genes with CNV in RCC (Chapter
2.3.3) revealed significant alterations in seven genes (MLH1, PMS2, MSH3, POLD2,
RFC2, RPA3, and SSBP1) of the MMR pathway. Every patient had a DNA methylation
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or CNV event in the MMR pathway and 81% of patients had either a significant DNA
methylation change, CNV event, or both at MSH4.

Figure 4.1 Consensus clustering of significant mismatch repair gene-related CpGs in all
renal cell carcinoma patients at k=2.
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4.3.2 A Subset of Renal Cell Carcinoma Patients Have Microsatellite Instability
To discover if the DNA methylation and CNV differences I detected in MMR
resulted in MSI, I performed PCR of the CRC Bethesda Panel loci and examined the
resulting products by denaturing polyacrylamide electrophoresis. Tumor and benign
adjacent kidney tissue target sizes were compared and differences were considered
microsatellite instability (Figure 4.2). A dilemma arises in cases of apparent loss of
heterozygosity (LOH) because it cannot be easily determined if this is true LOH or
rather, MSI where the shifted allele has migrated with the wild-type allele.

By

convention, these markers are not scored as MSI because the likelihood a shifted allele
would migrate with the remaining allele should be relatively low. Scoring markers in this
manner could bias results towards MSS, but studies in CRC have shown that patients
with MSI have a tendency to show instability at multiple markers, so the impact should
be minimal (Boland et al., 1998). Additionally, I examined the CNV data at regions
showing potential LOH, and found evidence of deletion events at these LOH sites (data
not shown).
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Figure 4.2 Examples of microsatellite stable, microsatellite instable, and loss of
heterozygosity events in renal cell carcinoma patients.(A) Patients with MSS show no
change from tumor (T) to adjacent normal (N) DNA. (B) Patients with MSI show a shift
in tumor compared to adjacent normal DNA. (C) Patients with LOH show allelic loss
compared to adjacent normal DNA.

Overall, I found MSI in at least one marker in 30.7% of all RCC patients, and in
36.4% of ccRCC patients. By the original Bethesda guidelines (Boland et al., 1998), in
CRC, tumors with a low level of MSI (MSI-L, i.e. a minority of markers exhibit MSI)
and a high level of MSI (MSI-H, i.e. a majority of markers exhibit MSI) are often
separated because the baseline mutation rate for microsatellites in CRC is not precisely
known and also because the detection of MSI is highly dependent on both the type of
markers used, the number of markers used (Boland et al., 1998), and the detection
method (Santos, Yamaoka, Graham, & Sepulveda, 1999).

Using this CRC MSI-H

criteria, only 4.0% of RCC patients were MSI-H and half of those were ccRCC patients.
My results were comparable to Altavilla, et al.'s study of MSI in 51 RCC patients using a
five marker panel (with two of the Bethesda panel targets)and both kidney tumor and
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benign adjacent normal tissue. They reported MSI of at least one marker in 31.4% of
tumors, and 5.9% of tumors demonstrated MSI-H (Altavilla et al., 2010). However, the
revised Bethesda guidelines recommend patients exhibiting MSI at 40% or more of
markers be classified as MSI-H, and by this metric, 13.9% of my patients are MSI-H
(Umar et al., 2004).
Next, I examined if there was a significant difference between any of the clinical
parameters in the MSI and MSS patients for all RCC patients and just the ccRCC
patients. For this analysis, MSI was defined as exhibiting MSI at any marker because of
the low frequency of MSI-H. I found no significant difference in age, gender, grade,
stage, or tumor size (Mann-Whitney test; Bonferroni adjusted p-value>0.05) in either
RCC or ccRCC patients with MSI, and also no significant difference in recurrence (log
rank test; p-value=0.9001 and p-value=0.5856, respectively).

4.3.3

Microsatellite Instability in Renal Cell Carcinoma Does Not Correlate with
DNA Methylation Alterations or Copy Number Variation in Mismatch
Repair Genes
I examined if the MSI status of patients (MSI-H and MSI-L considered MSI)

correlated with CNV or DNA methylation changes in MMR genes.

I found no

significant correlation between CNV changes in MMR genes and patient MSI status
(Mann Whitney test; BH adjusted p-value>0.05) or between DNA methylation changes in
MMR genes and patient MSI status (Mann Whitney; BH adjusted p-value>0.05).
Examining the ConsensusCluster results in Figure 4.1, I found 29.3% of the
patients in the larger cluster had MSI in at least one marker, while 33.3% of the patients
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in the smaller cluster had MSI in at least one marker.MSI status also was not significantly
associated with increased array DNA methylation (Wilcoxon, p-value=0.2263) or number
of genes with copy number variation (Wilcoxon, p-value=0.2619). I next performed a
linear regression analysis examining potential DNA methylation changes associated with
MSI status with age and gender as covariates, and I found no CpGs associated with MSI
status (BH adjusted p-value>0.05).

4.4 Discussion
Previous studies examining MSI in RCC had conflicting conclusions, most likely
as a result of underpowered studies, not using a standardized panel or method for
determining MSI, and protocols which may result in false negatives (Santos et al., 1999).
This study confirmed MSI occurs in a low percentage of RCC patients using fully
denaturing gel electrophoresis and the Bethesda panel,

the gold standard for MSI

identification in CRC patients (Boland et al., 1998; Umar et al., 2004). There was no
correlation between patient grade, stage, age, gender, subtype, or recurrence with MSI
status. Due to the small percentage of patients exhibiting MSI-H (4.0% by the Bethesda
guidelines (Boland et al., 1998) and 13.9% by the revised Bethesda guidelines (Umar et
al., 2004)) I may be underpowered to detect correlations with clinical parameters, or RCC
patients with MSI may not exhibit a distinct disease phenotype like MSI-H CRC patients
(Wong et al., 2007). CRC patients with MSI have demonstrated differing response to
chemotherapeutics (Devaud & Gallinger, 2013), and it remains to be seen if RCC patients
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with MSI respond differently as well, but RCC tumors are already known to be widely
resistant to chemotherapeutics (Jonasch et al., 2012).
To my knowledge, this is the first study examining MSI in RCC in the context of
genome-wide DNA methylation and CNV data. However, despite widespread DNA
methylation and CNV changes in MMR genes, I did not find a correlation between global
genetic variation and MSI status. Potentially, DNA methylation or CNV may not be
altered enough to cause a biologically significant change in downstream MMR pathway
protein levels or they may simply be passenger events (for example, MLH1 is located on
chromosome 3p, which is deleted in the majority of ccRCC patients (Stoehr et al., 2012)),
and therefore not affecting MSI at a widespread level. Additionally, the MMR pathway
genes MSH2 and MSH3 were recently implicated in the maintenance of chromosomal
instability through the DNA double-strand break repair pathway in p53 deficient mice, a
finding yet to be explored in RCC (van Oers et al., 2013).
While MSI at mono- and dinucleotide sequence repeats in RCC has been
investigated by many groups (Altavilla et al., 2010; Chen et al., 2000; Deguchi et al.,
2003; Diakoumis et al., 1998; Goessl et al., 1998; Kanomata et al., 1998; Leach et al.,
2002; Shin et al., 2000; Stoehr et al., 2012; Thrash-Bingham et al., 1995; Willers et al.,
1996), only one study has examined sequence instability in tetranucleotide repeats
(Stoehr et al., 2012) (they found one case in 166 tumors, but did not use fully denaturing
gel electrophoresis). Perhaps the MMR gene DNA methylation and CNV changes I saw
affect trinucleotide repeats or type B repeats (sequence modifications affecting repeats of
8 or more base pairs), neither of which has been previously studied in RCC. Other
studies found MMR gene alterations exclusively associated with repeats other than
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mono- or dinucleotide microsatellites in other cancers (Oda et al., 2005). While I (see
Chapter 2) and others (Cifola et al., 2008; Creighton et al., 2013; Sato et al., 2013) have
concluded there is widespread CNV in RCC, there has not been an investigation into
chromosomal instability affecting regions larger than three base pairs, but not associated
with broad chromosomal features.

Future studies could investigate if the DNA

methylation and CNV events I found in MMR genes, and the decrease in expression of
MMR genes and proteins reported by others in RCC (Altavilla et al., 2010; Rubio-DelCampo et al., 2008; Stoehr et al., 2012) affect these regions. Additionally, 81% of the
ccRCC patients had significant DNA methylation alterations in the gene promoter or
significant copy number events atMSH4, a gene associated with the MMR pathway and
related to the VHL pathway as an interacting partner with VBP1, a chaperone protein that
targets VHL (Her, Wu, Griswold, & Protein, 2003). MSH4 alterations may not disrupt
the MSI pathway, but instead the VHL pathway.
In this study, I confirmed MSI was not prevalent in a high percentage of RCC
patients. However, given the amount of DNA methylation changes and CNV in MMR
genes, and that genetic alterations in MMR genes have been associated with both
chemoresistance and prognosis (Chen et al., 2000; Leach et al., 2002), additional studies
to examine the role of decreased expression of MMR genes in RCC patients could yield
insights into RCC etiology and progression.
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CHAPTER 5

CONCLUSIONS AND FUTURE DIRECTIONS

5.1 Project Summary
Renal cell carcinoma (RCC) is difficult to diagnose because of a lack of
symptoms in early stages followed by non-specific symptoms in later stages. Patients are
cured only with successful surgery during early stages and those with metastatic disease
do not respond well to traditional chemotherapeutics.

In this study, I addressed

diagnostic and prognostic implications of DNA methylation alterations and CNVs in
parallel across 101 clinically-annotated RCC patients.
In Chapter 2, I demonstrated integrated analysis of resected kidney tumor and
benign adjacent kidney tissue with clinical information identified molecular changes and
pathways associated with RCC etiology.

I reported a panel of DNA methylation

biomarkers that successfully distinguish tumor from benign adjacent tissue and validated
these markers in The Cancer Genome Atlas RCC datasets. Additionally, variable DNA
methylation and copy number profiles effectively classified patients into distinct risk of
recurrence groups for potential assessment of alternative treatment therapies. I found
increased global DNA methylation is strongly correlated with increased incidence of
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recurrence, and there is a non-monotonic relationship between recurrence and global
levels of copy number events.
In Chapter 3, I identified widespread DNA methylation alterations and CNV
between different RCC subtypes.

Despite the similar pathological features of

oncocytomas and ChRCCs, I report DNA methylation changes and CNV differ between
the two subtypes. Additionally, I expanded upon work by others demonstrating increased
DNA methylation as a hallmark of pRCC. This is also the first genome-wide study of
DNA methylation and CNV in CCPRCC. Despite the low patient number, I found 38
CpGs differentially methylated between CCPRCC and the other four RCC subtypes.
In Chapter 4, I completed the first study of Bethesda panel markers in RCC
patients using fully denaturing electrophoresis in tandem with DNA methylation and
CNV genome-wide profiles, including MMR genes. Overall, I found widespread DNA
methylation alterations and CNV in MMR genes, but did not find a correlation between
these changes and MSI status. In fact, few patients demonstrated MSI-H (5.9% by
Bethesda guidelines and 13.9% by revised Bethesda guidelines).
Overall, these DNA methylation and copy number profiles provide powerful
insights into the etiology and recurrence of renal cell carcinoma, as well as provide
clinically applicable biomarkers for the diagnosis of RCC.
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5.2 Future Directions

5.2.1 Larger Studies with More Data Integration
In genomics, new techniques resulting in higher resolution and more precise
measurements, as well as novel analysis methods are constantly being developed.
Applying these techniques to RCC will result in a better understanding of the genetic
variation between kidney tumor and kidney benign tissue, as well as between different
RCC subtypes, and between patients with varying recurrence and survival rates.
Additionally, examining CNV and DNA methylation profiles with RNA and protein
expression is likely to uncover functional changes caused by CNV and DNA methylation
alterations.

By continuing to integrate additional genomic data sets and increase

detection power with higher patient numbers, a more complete understanding of genetic
variation in RCC can be achieved.

5.2.2 Diagnostic Biomarker Panels
In Chapter 2, I reported diagnostic biomarker panels for both general RCC and
ccRCC specifically.

Other studies have demonstrated the potential for measuring

promoter DNA methylation in RCC patient urine and serum DNA (Battagli et al., 2003;
Hoque et al., 2004), and because of the high sensitivity and specificity of the biomarkers
in both general RCC and ccRCC, these panels are prime candidates for the development
of clinical tests for early RCC detection. These biomarkers might also function to
distinguish between small benign and malignant lesions and as an early marker for
recurrence by following patients after tumor resection.
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A future study including

collection of patient blood, urine, kidney tumor tissue, and adjacent kidney normal tissue
of RCC patients would establish the utility of these biomarkers in the clinic.

A

comparison of DNA methylation levels across blood, urine, and kidney tissue could be
used to develop a blood or urine test for the detection of RCC and compared to blood or
urine in people without RCC. Additionally, RNA and protein expression of the genes
associated with these CpGs could be examined to determine if DNA methylation
alterations at these loci result in functional consequences at the RNA and protein level.

5.2.3 Renal Cell Carcinoma Cell Lines and Pharmaceutical Testing
Additionally, I identified differential DNA methylation and CNV in genes related
to GPCR function and immune-related pathways between patient groups with varying
recurrence rates.

Future studies in RCC cell lines characterized for these DNA

methylation alterations and CNV events could examine if drugs modulating cell behavior
based on GPCR or immune function are viable options as RCC chemotherapeutics.
Because there are already a wide variety of pharmaceuticals targeting these pathways
available and because of the lack of effective chemotherapeutics for late stage RCC, this
could provide insight into new drugs for use in RCC.
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APPENDICES
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APPENDIX A

PATIENT INFORMATION

Tumor and adjacent benign kidney tissues used in this study were collected at
Stanford University with patient's informed consent under IRB-approved protocols at
both Stanford University and The HudsonAlpha Institute for Biotechnology.

Clinical

data was collected for all patients, including follow-up and recurrence data on 80 of these
patients. Patient grade, stage, and age were compatible with risk of recurrence (Howlader
et al., 2009). Tissue sections were examined by a pathologist and clinical information
associated with the patients is summarized in Table A.1.
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Table A.1 Patient distributions of clinical parameters.

Clinical Parameter
RCC Histological Subtype

Gender
Grade
Stage
Surgery Type
Margin Status
Tumor Size

Age

Patient Distribution
66 ccRCC, 10 ChRCC, 7 pRCC, 4
ccRCC/sarcomatoid, 4 oncocytoma, 3
sarcomatoid, 3 CCPRCC, 2 transitional,
1 Wilms, and 1 unclassified
38 female, 63 male
11 grade 1, 45 grade 2, 26 grade 3, 15
grade 4, 4 unclassified
36 stage 1, 21 stage 2, 31 stage 3, 12
stage 4, 1 unclassified
38 laproscopic, 62 open, 1 radical
95 negative, 6 positive
Tumors range from 2.0 cm to 22.0 cm
with a mean size of 7.6 cm (standard
deviation=±4.0 cm)
Ages range from 2 to 87 years old with a
mean age of 62 years old (standard
deviation=±13.7 years)
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APPENDIX B

CHAPTER 2SUPPLEMENTAL FIGURES

Figure B.1 Remaining diagnostic panel biomarker CpG values from diagnostic models.
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Figure B.1 (continued) DNA methylation at the 5 CpGs in both HAIB/Stanford patients
and TCGA patients from the best RCC diagnostic model (cg13156411, cg14456683,
cg18003231, cg12782180, and cg12782180; panel A-E), and the other 3 CpGs in both
HAIB/Stanford patients and TCGA patients in the best ccRCC diagnostic model
(cg11098259, cg14391855, and cg26366091; panel F-H). In all panels, HAIB/Stanford
Data N versus HAIB/Stanford Data T and TCGA Data N versus TCGA Data T
comparisons are significant (Mann-Whitney test; Bonferroni adjusted p-value<0.0001).
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Figure B.2 RNA expression for genes nearest the other 3 CpGs predictive of tumor or
normal tissue in ccRCC. RNA expression of the 3 other genes in both HAIB/Stanford
patients and TCGA patients in the best ccRCC diagnostic model (panel A-C, MannWhitney test; p-value<0.0001). The CpGs are all in the promoter regions of the
respective genes.
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Figure B.3 Consensus cluster after shuffling patient labels. Consensus clustering of all
26,148 CpGs and 99 tumor tissues at k=7 after shuffling of the sample labels. A K-S test
between data and shuffled data distributions had a p-value<0.000001.
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Introduction to Remaining Appendices

The following appendices are important units of work not included in Chapters 2,
3, or 4. In Appendix C, I calculate statistical power for diagnostic and prognostic DNA
methylation biomarkers, explaining why I could not identify prognostic biomarkers (see
Appendix F) with the same statistical power of the diagnostic biomarker panels reported
in Chapter 2. In Appendix D, I identify CpGs associated with increasing grade in ccRCC
patients. Appendix E compares the linear mixed effects model results in Chapter 2.3.1
with compatible non-parametric method results, and Appendix G describes Chapter 2.3.4
consensus clustering analysis, including ccRCC patients only.

In Appendix H, I

demonstrate proof-of-concept for identifying levels of copy number variation in tumor
tissues via DNA methylation measurements. Finally, Appendix I reports the correlation
between RRBS and HumanMethylation27k DNA methylation measurements, and
Appendix J describes an attempt to validate CNV findings with a digital droplet PCR
system.
Rick Myers, Devin Absher, and Jim Brooks assisted with planning experiments
and analyzing data. I worked with Devin Absher and his lab to perform the DNA
methylation and copy number variation assays.

Preti Jain performed ComBat

normalization of the DNA methylation data. Todd Burwell contributed to the statistical
analysis, particularly Appendix C.
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APPENDIX C

POWER CALCULATIONS FOR DIAGNOSTIC AND PROGNOSTIC DNA
METHYLATION BIOMARKERS

To examine statistical power in this data set for the identification of diagnostic or
prognostic DNA methylation biomarkers in either all RCC patients or only ccRCC
patients, I performed power calculations. In statistics, a Type I error is when a researcher
rejects the null hypothesis (Ho) when it is defined as true. The probability of a Type I
error is denoted as α= P(reject Ho when Ho is true). A Type II error is failing to reject Ho
when it is false. The probability of a Type II error is denoted as β = P(fail to reject Ho
when Ho is false). Finally, the power of a statistical test is the probability of rejecting Ho
when the alternative is true. Power is computed as 1 - β (Montgomery & Runger, 1999).
Most of the DNA methylation findings in this project relied on linear regression
analysis:
Y=βo + β1X + ε

(C.1)
94

where Y is the response or dependent variable, βo is the intercept, β1 is the slope or
regression coefficient, X is the regressor or independent variable, and ε is a random error
component with the assumed distribution N(0,σ2). For regression analysis the hypothesis
test for the significance of regression is:
HO: 𝛽1 =0

(C.2)

H1: 𝛽1 ≠0

(C.3)

where𝛽1 is the slope, HO is the null hypothesis, and H1 is the alternate hypothesis.
Failing to reject the null hypothesis implies no significant linear relationship between the
regressor and response variables(Montgomery & Runger, 1999). A t-test can be used to
determine whether the regression line slope differs significantly from zero (Montgomery,
Peck, & Vining, 2003). I calculated statistical power for various questions posed in this
project with t-tests of means using the pwr.t2n.test function in the R pwr package (Cohen,
1988). Power is dependent on the number of observations in both samples (n1, n2), Type
I error probability (α), and effect size (d). Assuming a two-tailed test and a Type 1 error
of 0.05, I generated curves displaying the relationship between power and effect size for
different sample sizes corresponding to diagnostic and prognostic questions in the RCC
or ccRCC data sets (Figure C.1). Examination of the curves reveals they become wider,
as expected, with less samples indicating a greater effect size is needed to retain the same
power (Table C.1).
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Figure C.1 Power and effect size for diagnostic and prognostic DNA methylation
biomarkers for this study. For cases, power across varying effect size was calculated
given a two-tailed test with α=0.05: (A) Tumor and normal differences (diagnostic) in
all RCC patients (96 tumor and 96 benign adjacent normal tissues). (B) Tumor and
normal differences (diagnostic) in ccRCC patients (63 tumor and 63 benign adjacent
normal tissues). (C) Non-recurrent and recurrent tumor differences (prognostic) in all
RCC patients (55 non-recurrent and 25 recurrent tumor tissues). (D) Non-recurrent and
recurrent tumor differences (prognostic) in ccRCC patients (37 non-recurrent and 16
recurrent tumor tissues).
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Table C.1 Decreasing sample size (n1, n2) requires increasing effect size (d) to retain the
same statistical power.

Case
Tumors vs. Normals for all RCC patients
Tumors vs. Normals for ccRCC patients
Non-recurrent Tumors vs. Recurrent Tumors for
RCC Patients
Non-recurrent Tumors vs. Recurrent Tumors for
ccRCC Patients

n1
96
63
55

n2
96
63
25

d
0.41
0.50
0.68

power
0.80
0.80
0.80

37

16

0.85

0.80

This project was successful at detecting validated DNA methylation diagnostic
biomarkers (Chapter 2), but was unable to detect DNA methylation prognostic
biomarkers, so I investigated if this was due to an under-powered data set. For example,
for the ccRCC diagnostic biomarkers, the diagnostic biomarkers had an associated power
range of 0.86 to 1.

By comparison, examining linear regression model results of the

ccRCC non-recurrent and recurrent tumors, I find the most significant CpGs, after BH
adjustment, have p-values of 0.630168. Examining the sample means, I found effect
sizes of approximately 0.6 with an associated power of 0.5 for these prognostic DNA
methylation markers. In this data set, 30% of the ccRCC patients with clinical follow-up
had recurrent kidney cancer, so in order to achieve statistical power of at least 0.86 (like
the least powerful diagnostic biomarker), I would need to increase sample size by adding
approximately 75 patients. To reach statistical power approaching 1, I would need to
increase sample size by adding approximately 250 patients. Visual inspection of the most
significant diagnostic CpG, cg04511534 (linear mixed model BH adjusted p-value=7.72
X 10-28)and prognostic CpG, cg1167380 (linear regression model BH adjusted
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p-value=0.630168) underscores that even though both have significant t-test p-values
(p<0.001 and p=0.0418, respectively) and therefore significantly different sample means,
the sample means are closer together for the most significant prognostic CpGs, and
coupled with smaller sample numbers, additional patients are required for this data set to
have the same statistical power for prognostic CpGs as diagnostic CpGs (Figure C.2).
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Figure C.2 Example CpGs for diagnostic and prognostic ccRCC biomarkers. (A)
Cg04511534 has significantly different means between HAIB N and HAIB T tissues
(t-test, p-value<0.0001). (B) Cg1167380 also has significantly different means between
non-recurrent and recurrent tumor tissues (t-test, p-value=0.0418).
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APPENDIX D

DNA METHYLATION MARKERS OF GRADE IN CLEAR CELL RENAL CELL
CARCINOMA

CpGs with significant DNA methylation changes (BH adjusted p-value<0.05)
corresponding to grade were identified by a linear regression model with age as a
covariate for all ccRCC tumor tissues. I found 18 CpGs associated with tumor grade
(Table D.1). Previous studies have demonstrated an increase in promoter methylation
with increasing grade and stage(Creighton et al., 2013), and here I report a panel of CpGs
associated with tumor grade.
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Table D.1 CpGs associated with tumor grade in ccRCC.

CpG
cg21546671
cg20588892
cg01618660
cg03626672
cg13105904
cg09620798
cg20595215
cg27606341
cg18988110
cg08458487
cg13666340
cg11827595
cg21091679
cg11024597
cg08815403
cg14654385
cg24092914
cg01526089

Associated Gene
HOXB4
TMEM161B
TRIM14
CXCR7
KHNYN
UBA3
LMCD1
FYB
PRR15L
SFTPD
SPATA6L
BRK1
ELL2
ECRG4
HSD17B13
FERMT3
VHL
P2RX1
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One of these significant CpGs (cg24092914) is in the first intron of VHL and has
decreasing methylation with increasing grade (Figure D.1). VHL is typically inactivated
in ccRCC because of chromosome 3p deletion or biallelic promoter hypermethylation.
However, a recent study reported that while VHL is typically inactivated in ccRCC and
not correlated with clinical outcome, during cancer progression there are diverse
epigenetic alterations in the VHL-HIF pathway corresponding to metastasis and poor
clinical outcome (Vanharanta et al., 2013). While decreasing DNA methylation at VHL
itself was not one of the alterations described in that study, additional studies examining
if DNA methylation changes in the promoter and first intron of VHL act as another
avenue for VHL-HIF re-activation associated with cancer progression.
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Figure D.1 Decreasing DNA methylation at cg24092914 (first intron of VHL) is
associated with increasing tumor grade (linear regression, BH adjusted p-value<0.05).

Another grade-associated CpG, cg27606341, is in the promoter of FYN binding
protein (FYB), a gene involved in T-cell signaling cascades, platelet activation, and
expression control of interleukin-2. Cg27606341 exhibits decreasing DNA methylation
with increasing grade (Figure D.2). Interestingly, FYB methylation and expression has
been associated with an hsa-miR-142 signature in multiple cancers that may signal
progressive loss of cell-cell adhesion (Andreopoulos & Anastassiou, 2012).
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Figure D.2 Decreasing DNA methylation at cg27606341 (promoter of FYB) is associated
with increasing tumor grade (linear regression, BH adjusted p-value<0.05).

This panel of CpGs associated with grade might provide insights on cancer
progression. Additional studies should examine the role of these genes in ccRCC cell
lines or determine if this set of CpGs could help pathologists determine tumor grade for
in ccRCC patient tumors.
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APPENDIX E

COMPARISON OF IDENTIFIED DNA METHYLATION ALTERATIONS BETWEEN
TUMOR AND BENIGN KIDNEY TISSUE BY NON-PARAMETRIC STATISTICAL
ANALAYSIS OF MICROARRAYS AND PARAMETRIC LINEAR MIXED MODEL
REGRESSION METHODS

In Chapter 2, I identified tumor-specific DNA methylation changes by performing
a linear mixed effects model with paired tumor/normal data at each CpG. This model
treated patient ID as a random effect and included gender and age as fixed effects. When
I analyzed all CpGs and patients, 9,800 CpGs were significantly different between kidney
tumor and benign adjacent kidney tissue (FDR<0.05).
I explored other analysis methods to identify tumor-specific alterations, including
the Statistical Analysis of Microarrays (SAM) (Tusher, Tibshirani, & Chu, 2001)
package. SAM is a non-parametric technique where a score is assigned to each CpG
based on the change in DNA methylation relative to the standard deviation of repeated
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measurements. For CpGs with scores greater than an adjustable threshold, SAM uses
permutations of repeated measurements to estimate an FDR.

This SAM analysis

included all 96 patient tumor and benign adjacent normal tissues and all 26,148 CpGs, of
which 20,480 CpGs were significant (FDR<0.05).

Comparison of the linear mixed

effects model results with the SAM results revealed 9,792 of the significant linear mixed
effects model CpGs were also significant in the SAM analysis (Figure E.1).

Figure E.1 Overlap of significant CpGs between linear mixed effects model(LMM) and
SAM methods for identification of tumor-specific DNA methylation in RCC patients.
For 96 patients, 26,148 CpGs were tested for significance between kidney tumor and
kidney benign adjacent normal tissues by SAM and by LMM with gender and age as
fixed effects. All but eight of the CpGs significant in the LMM analysis were significant
in the SAM analysis.

As Figure E.1 clearly depicts, all but eight of the CpGs significant by linear mixed
effects model analysis were also significant with SAM. However, a much larger subset
of CpGs was significant with the SAM analysis. There are several reasons why there
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could be more significant CpGs identified by SAM when compared to linear mixed
effects models. For example, because SAM is a non-parametric analysis that does not
make assumptions about the distribution of the data, CpGs may be significant in SAM,
but not in a parametric analysis. Also, the linear mixed effects model analysis included
gender and age as fixed effects and both can significantly affect DNA methylation levels
(Bocklandt et al., 2011; Boks et al., 2009; Day et al., 2013; Rakyan et al., 2010; Salpea et
al., 2012). Ultimately, because of these covariates and their known association with
DNA methylation, Chapter 2 reports tumor-specific DNA methylation alterations using
linear mixed effects model analysis.
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APPENDIX F

EXPLORING PROGNOSTIC APPLICATIONS OF THE DIAGNOSTIC
DNA METHYLATION BIOMARKER PANEL

After establishing a panel of diagnostic biomarkers for ccRCC (described in
Chapter 2), a literature search of the genes nearest these CpGs (all 11 CpGs are in the
promoter region or first intron of the associated gene) revealed two of the associated
genes were previously associated with poor response in cancer patients: aquaporin-9
(AQP9) and ras and rab interactor 1 (RIN1). AQP9 encodes a protein that allows passage
across the cell membrane of non-charged particles and stimulates urea transport and
water permeability, and expression of AQP9 was implicated as an indicator of nonresponse to chemotherapeutics in colorectal cancer(Dou et al., 2013). RIN1 effects RAS
signaling in multiple ways and overexpression is associated with higher grade and poorer
prognosis in several cancers, including gastric adenocarcinoma (Yu et al., 2012),
hepatocellular carcinoma (He et al., 2013), melanoma (Fang et al., 2012), and bladder
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urothelial carcinoma (Shan et al., 2012).

Additionally, WNT1 inducible signaling

pathway protein 2 (WISP2) may be involved in malignant transformation.

In breast

adenocarcinomas WISP2 expression is biphasic and high WISP2 levels are associated
with non-invasive tumors (Banerjee et al., 2008). Finally, serum amyloid A1 (SAA1) is
highly expressed during inflammation and has been previously implicated in kidney
cancer as a potential Wilms tumor marker (Wang et al., 2012), as one of a two protein
signature model for prognosis prediction in metastatic renal cell carcinoma (Vermaat et
al., 2010), and as a predictor of fatal outcome in renal cell carcinoma (Paret et al., 2010).
Because 40% of the genes represented on the diagnostic panel have known
prognostic cancer implications in the literature, I attempted to build a prognostic model
for ccRCC from the 11 diagnostic CpGs using the methods described in Chapter 2, but
now with two ccRCC prognostic groups: 37 ccRCC patients with non-recurrent kidney
cancer and 16 ccRCC patients with recurrent kidney cancer.
I established a 3 CpG model (cg04511534, cg14391855, andcg26366091) with a
ROC curve area of 0.958 and a BH adjusted p-value of 5.22 X 10-7 (Figure F.1). When I
apply this model to the TCGA data (145 non-recurrent ccRCC patients and 48 recurrent
RCC patients), I correctly identify 87.8% of non-recurrent patients and 18.8% of
recurrent patients.

Using the 11 CpG panel and asking what the most predictive

prognostic model I can build in the TCGA data is, the best 3 CpG model is still
cg04511534, cg14391855, and cg26366091, but the ROC curve area is0.714 with a BH
adjusted p-value of 4.66 X 10-4.

Taken together, this suggests over-fitting of the

prognostic 3 CpG model (see Appendix C), and while these diagnostic CpGs have some
prediction capability when asking about recurrence or non-recurrence, their value as
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prognostic biomarkers is limited without future studies including many more clinicallyannotated patients (see Appendix C).

Figure F.1 ROC curve of HAIB 3 CpG prognostic models. The ROC curve is shown
with the best model (aqua), the average of the ten best models (yellow), a gradient
representing all of the models analyzed (blue), and the line of no information (black).
Area under the ROC curve for the best model is 0.958 and the BH adjusted p-value is
5.22 X 10-7.
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APPENDIX G

CONSENSUS CLUSTERING OF CLEAR CELL RENAL CELL CARCINOMA
TUMOR TISSUE DNA METHYLATION

The DNA methylation data used is described in Chapter 2.2.1, 2.2.2, and 2.2.3.
To look for patient subgroups in the ccRCC DNA methylation data set, I used the R
package ConsensusCluster Plus(Wilkerson & Hayes, 2010)on all 26,148 CpGs and 64
ccRCC tumor tissues with k-means clustering from k=2 to k=10. To ask whether clusters
correlate with clinical data, I plotted Kaplan-Meier curves for the subgroups from each k
and determined k=6 had the most significant Kaplan-Meier curve (log-rank test,
Bonferroni adjusted p-value=0.0477) (Figure G.1 and G.2). To further evaluate the
significance of the clusters, I performed a consensus cluster after shuffling the tumor
labels in the data, and found no discernible clustering pattern (K-S test between data and
shuffled data distributions, p-value<0.000001) (Figure G.3).
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Figure G.1 Consensus clustering of ccRCC tumor tissues with DNA methylation data.
Consensus clustering of ccRCC tumor tissues by all DNA methylation data (26,148
CpGs).
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Figure G.2 Kaplan-Meier curve of patients by consensus cluster group at k=6. KaplanMeier curve of patients by consensus cluster group (log-rank test, Bonferroni adjusted
p-value=0.0477).
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Figure G.3 Consensus cluster of ccRCC DNA methylation data after shuffling tissue
labels. Consensus clustering of all 26,148 CpGs and 64 tumor tissues at k=6 after
shuffling of the tissue labels. A K-S test between data and shuffled data distributions had
a p-value<0.000001.
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After establishing clusters, I examined the level of DNA methylation across all
the CpGs and across the most variant CpGs within each cluster and between each cluster.
I found a significant difference across the six clusters (Kruskal-Wallis test,
p-value<0.0001). When I examine the average DNA methylation across only the most
variant CpGs (standard deviation>0.2, 109 CpGs), the trend in increasing DNA
methylation across clusters is magnified. I also examined the frequency of genes with a
copy number event per patient in each cluster and found a significant trend, most notably
where cluster 1 had a higher incidence of chromosomal instability compared with the
other clusters (Kruskal-Wallis, p-value<0.05).
Previous work showed ccRCC clusters defined by unsupervised hierarchical
clustering with more DNA methylation have poorer prognosis (Arai et al., 2012), but this
is the first study utilizing a consensus algorithm to establish clusters and examine gross
CNV also.
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APPENDIX H

METHYL-CIN

There is value in the ability to infer genomic changes of one type from another.
For example, Carter et al. reported a computational method for characterizing
aneupoloidy in tumor tissues based on a 70 gene expression signature, named CIN70
(Carter et al., 2006). In my data set I asked if I could identify CpG DNA methylation
alterations that correlate with the level of copy number variation in a tumor tissue
(dubbed "METHYL-CIN").

This would allow researchers to infer chromosomal

instability from DNA methylation data. I performed a linear regression model with age
as a covariate examining changing DNA methylation between the four CNV groups
established in Chapter 2.3.5.

I found 8,831 CpGs significantly different across the

different copy number groups (BH-adjusted p-value<0.05).

For example, the most

significant CpG (BH-adjusted p-value=3.19 X 10-11) is a CpG in the promoter of
programmed cell death 1 ligand 2 (PDCD1LG2), a gene involved in the negative
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proliferation of T-cells by blocking cytokine production and cell cycle progression
(Figure H.1).

Figure H.1 1DNA methylation at cg07211259 (promoter of PCD1LG2) increases with
increasing global copy number events in kidney tumor tissue.

By utilizing publically available genomics data from projects like TCGA, it may
be possible to develop a panel of CpGs identifying levels of aneupoloidy in numerous
tumor tissues, instead of just RCC, similar to the CIN70 expression/CNV panel. TCGA
has genomics data for over 20 different cancers and thousands of tumor tissues. By
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dividing the available data into a training set and a test set, I could establish a panel using
DNA methylation as a surrogate for cancer cell copy number levels.
Additionally, studies have examined the impact of copy number variation on
DNA methylation measurements, and found with bead-array assays, only minor
variations in measured DNA methylation levels due to copy number variation (except in
cases of homozygous deletion). One hypothesis is increasing copy number may not
correspond to increases in DNA methylation, because within these regions clones may be
selected for that have increased copy number correlating with increased expression
(Houseman et al., 2009). A broader study including more patients, more cancer tissues,
and multiple methods for measuring both copy number variation and DNA methylation
might yield a robust panel for inferring copy number variation from DNA methylation, as
well as provide insight into the relationship between copy number events and DNA
methylation alterations.
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APPENDIX I

COMPARISON OF REDUCED REPRESENTATIVE BISULFITE SEQUENCING
AND HUMANMETHYLATION27 RESULTS

As part of this project, I utilized a sequencing method for measuring DNA
methylation across the genome called Reduced Representative Bisulfite Sequencing
(RRBS) (Meissner et al., 2005)and compared measured CpG methylation between RRBS
and HumanMethylation27 data. The protocol was performed as described by Varley, et
al. (Varley et al., 2013) on 12 tumor kidney tissues and 2 benign adjacent kidney tissues.
I averaged detection of 804,422 CpGs with 10X or greater coverage (range: 619,976976,034 CpGs).
Comparing DNA methylation levels at CpGs shared between RRBS and
HumanMethylation27, I found increasing coverage in RRBS resulted in an increased
correlation between RRBS and HumanMethylation27measurements (Figure I.1), which is
not surprising because of the increased precision in RRBS measurements with increasing
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coverage. These results, along with the TCGA validation results in Chapter 2.3.2 provide
technical and biological validation for the DNA methylation results.
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Figure I.1 Comparison of DNA methylation measurements by RRBS and Methylation27
assays at varying RRBS coverage in a kidney tumor tissue. (A) At 10X RRBS coverage,
996 CpGs are assayed by both methods (R2=0.7649). (B) At 20X RRBS coverage, 547
CpGs are assayed by both methods (R2=0.8161). (C) At 30X RRBS coverage, 284
CpGs are assayed by both methods (R2=0.8331).
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APPENDIX J

COMPARISON OF DIGITAL DROPLET PCR AND
HUMAN 1M-DUO COPY NUMBER VARIATION RESULTS

Digital droplet PCR (ddPCR) is a method where the DNA sample is partitioned
into ~20,000 oil droplets, a qPCR reaction is performed, and then each droplet is read as
either PCR positive or PCR negative for the targeted molecule and positive and negative
droplets are summed to quantify the results (Beer et al., 2008; Hussein et al., 2011;
Williams et al., 2010). By utilizing FAM and VIC assays together in the same reaction,
qPCR targeting the CNV region of interest with a FAM dye label, and a reference assay
targeting a diploid region can be implemented with a VIC dye label. By comparing a
ratio of the two ddPCR results, copy number variation for the region is determined.
Experiments were performed for six loci of interest chosen from the CNV results
(Chapter 2.2.4) and performed via manufacturer's directions (QuantaLife).

I first

established the reproducibility of the technology by testing gDNA at a loci known to be
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diploid in multiple reactions. I found an expected copy number of 2.00 (average of four
trials: 2.09, 1.96, 1.99, and 1.97).
Next I tested the dynamic range of the technology by amplifying the region of
interest with PCR, concentrating the PCR product with a column, quantifying the
resulting sample, and adding specific amounts of DNA to ddPCR reactions corresponding
to an additional 1, 2, 3, 4, or 5 copies, mimicking a sample with 3 copies to 7 copies.
Overall, I found great agreement from 2 copies to 5 copies and an increase in reported
CNV with 6 and 7 copies, but not at the same linear rate as the 2 copy to 5 copy range
(Figure J.1).

Figure J.1 DNA spike-ins from 2 copies to 7 copies in ddPCR.
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After establishing reproducibility and the ability to detect varying copy number, I
began testing regions of significant CNV reported in Chapter 2. Unfortunately, I was
unable to reproduce the CNV results from the Illumina Human 1M-Duo assays because
the tumor DNA had CNV events at the reference loci, and I could not properly establish
diploid as a baseline. By examining the reference assay targets in the Illumina Human
1M-Duo CNV data, I confirmed the reference loci targets were likely not diploid at these
loci in the majority of patients, likely a common problem when applying this particular
system to any cancer copy number variation project. In the future, amending the software
to allow for cross-well calculations so a patient's tumor DNA level can be directly
compared to the patient's normal DNA level would bypass needing a reference assay.
Alternatively, a spike-in assay with an "absolute CNV count" that can be adjusted based
on sample concentration might also solve this problem.
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